#BEGIN_DRUGCARD DB02687

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
7322-31-8

# ChEBI_ID:
28563

# Chemical_Formula:
C6H12O6

# Chemical_IUPAC_Name:
(2S,3S,4R,5R,6S)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Beta-D-Mannose

# HET_ID:
BMA

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3-,4+,5-,6-/m0/s1

# InChI_Key:
InChIKey=WQZGKKKJIJFFOK-QYESYBIKSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
C02209

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
2687

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
180.1559

# Molecular_Weight_Mono:
180.063388116

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1L7G

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-2.6

# Predicted_LogS:
0.64

# Predicted_Water_Solubility:
7.82e+02 g/l

# Primary_Accession_No:
DB02687

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
6992084

# PubChem_Substance_ID:
46508359

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT00721

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC[C@@H]1O[C@H](O)[C@@H](O)[C@H](O)[C@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:21:23 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_10_Cellular_Location:
Cytoplasmic

# Drug_Target_10_Chromosome_Location:
Not Available

# Drug_Target_10_Drug_References:
Not Available

# Drug_Target_10_Essentiality:
Non-Essential

# Drug_Target_10_GenAtlas_ID:
Not Available

# Drug_Target_10_GenBank_ID_Gene:
M93130

# Drug_Target_10_GenBank_ID_Protein:
Not Available

# Drug_Target_10_GeneCard_ID:
Not Available

# Drug_Target_10_Gene_Name:
Not Available

# Drug_Target_10_Gene_Sequence:
>10173 bp
ATGAACAACCAACGGAAAAAGACGGGAAAACCGTCTATCAATATGCTGAAACGCGTGAGA
AACCGTGTGTCAACTGGATCACAGTTGGCGAAGAGATTCTCAAGAGGATTGCTGAACGGC
CAAGGACCAATGAAATTGGTTATGGCGTTTATAGCTTTCCTCAGATTTCTAGCCATTCCA
CCGACAGCAGGAGTCTTGGCTAGATGGGGTACCTTTAAGAAGTCGGGGGCTATTAAGGTC
TTAAAAGGCTTCAAGAAGGAGATCTCAAACATGCTGAGCATTATCAACAAACGGAAAAAG
ACATCGCTCTGTCTCATGATGATGTTACCAGCAACACTTGCTTTCCACTTAACTTCACGA
GATGGAGAGCCGCGCATGATTGTGGGGAAGAATGAAAGAGGAAAATCCCTACTTTTTAAG
ACAGCCTCTGGAATCAACATGTGCACACTCATAGCCATGGATTTGGGAGAGATGTGTGAT
GACACGGTCACTTACAAATGCCCCCACATTACCGAAGTGGAGCCTGAAGACATTGACTGT
TGGTGCAACCTTACATCGACATGGGTGACTTATGGAACATGCAATCAAGCTGGAGAGCAT
AGACGCGATAAGAGATCAGTGGCGTTAGCTCCCCATGTCGGCATGGGACTGGACACACGC
ACTCAAACCTGGATGTCGGCTGAAGGAGCTTGGAGACAAGTCGAGAAGGTAGAGACATGG
GCCCTTAGGCACCCAGGGTTTACCATACTAGCCCTATTTCTTGCCCATTACATAGGCACT
TCCTTGACCCAGAAAGTGGTTATTTTTATACTATTAATGCTGGTTACCCCATCCATGACA
ATGAGATGTGTGGGAGTAGGAAACAGAGATTTTGTGGAAGGCCTATCGGGAGCTACGTGG
GTTGACGTGGTGCTCGAGCACGGTGGGTGTGTGACTACCATGGCTAAGAACAAGCCCACG
CTGGACATAGAGCTTCAGAAGACTGAGGCCACTCAGCTGGCGACCCTAAGGAAGCTATGC
ATTGAGGGAAAAATTACCAACATAACAACCGACTCAAGATGTCCCACCCAAGGGGAAGCG
ATTTTACCTGAGGAGCAGGACCAGAACTACGTGTGTAAGCATACATACGTGGACAGAGGC
TGGGGAAACGGTTGTGGTTTGTTTGGCAAGGGAAGCTTGGTGACATGCGCGAAATTTCAA
TGTTTAGAATCAATAGAGGGAAAAGTGGTGCAACATGAGAACCTCAAATACACCGTCATC
ATCACAGTGCACACAGGAGACCAACACCAGGTGGGAAATGAAACGCAGGGAGTTACGGCT
GAGATAACATCCCAGGCATCAACCGCTGAAGCCATTTTACCTGAATATGGAACCCTCGGG
CTAGAATGCTCACCACGGACAGGTTTGGATTTCAATGAAATGATTTTATTGACAATGAAG
AACAAAGCATGGATGGTACATAGACAATGGTTCTTTGACTTACCCCTACCATGGACATCA
GGAGCTACAACAAAAACACCAACTTGGAACAGGAAAGAGCTTCTTGTGACATTTAAAAAT
GCACATGCAAAAAAGCAAGAAGTAGTTGTCCTTGGATCACAAGAGGGAGCAATGCATACA
GCACTGACAGGAGCTACAGAGATCCAAACCTCAGGAGGCACAAGTATTTTTGCGGGGCAC
TTAAAATGTAGACTCAAGATGGACAAATTGAAACTCAAGGGGATGAGCTATGCAATGTGC
TTGAATACCTTTGTGTTGAAGAAAGAAGTCTCCGAAACGCAGCATGGGACAATACTCATT
AAGGTTGAGTACAAAGGGGAAGATGCACCCTGCAAGATTCCTTTCTCCACGGAGGATGGA
CAAGGGAAAGCTCACAATGGCAGACTGATCACAGCCAATCCAGTGGTGACCAAGAAGGAG
GAGCCTGTCAACATTGAGGCTGAACCTCCTTTTGGGGAAAGTAATATAGTAATTGGAATT
GGAGACAAAGCCCTGAAAATCAACTGGTACAGGAAGGGAAGCTCGATTGGGAAGATGTTC
GAGGCCACTGCCAGAGGTGCAAGGCGCATGGCCATCTTGGGAGACACAGCCTGGGACTTT
GGATCAGTGGGTGGTGTTTTGAATTCATTAGGGAAAATGGTCCACCAAATATTTGGGAGT
GCTTACACAGCCCTATTTAGTGGAGTCTCCTGGATAATGAAAATTGGAATAGGTGTCCTC
TTAACCTGGATAGGGTTGAATTCAAAAAACACTTCTATGTCATTTTCATGCATTGCGATA
GGAATCATTACACTCTATCTGGGGGTCGTGGTGCAAGCTGACATGGGGTGTGTCATAAAC
TGGAAAGGCAAAGAACTCAAATGTGGAAGTGGAATTTTCGTCACTAATGAGGTCCACACC
TGGACAGAGCAATACAAATTTCAAGCAGACTCCCCCAAAAGAGTGGCAACAGCCATTGCA
GGCGCTTGGGAGAATGGAGTGTGCGGAATTAGGTCAACAACCAGAATGGAGAACCTCTTG
TGGAAGCAAATAGCCAATGAACTGAACTACATATTATGGGAAAACGACATTAAATTAACG
GTAGTTGTAGGCGACATAACTGGGGTCTTAGAGCAAGGGAAAAGAACACTAACACCACAA
CCCATGGAGCTAAAATATTCTTGGAAAACATGGGGTTTGGCAAAAATAGTGACAGCTGAA
ACACAAAATTCCTCTTTCATAATAGATGGGCCAAGCACACCGGAGTGTCCAAGTGCCTCA
AGAGCATGGAATGTGTGGGAGGTGGAAGATTACGGGTTCGGAGTTTTCACAACCAACATA
TGGCTGAAACTCCGAGAGGTGTACACCCAACTATGTGACCATAGGCTAATGTCGGCAGCC
GTCAAGGATGAGAGGGCCGTACACGCCGACATGGGCTATTGGATAGAAAGCCAAAAGAAT
GGAAGTTGGAAGCTAGAAAAAGCATCCCTCATAGAGGTGAAAACCTGCACATGGCCAAAA
TCACACACTCTTTGGAGCAATGGTGTGCTAGAGAGTGACATGATTATCCCAAAGAGTCTA
GCTGGTCCCATTTCGCAACACAACCACAGGCCCGGGTACCACACCCAAACGGCAGGACCC
TGGCACTTAGGAAAATTGGAGCTGGACTTCAACTATTGTGAAGGAACAACAGTTGTCATC
TCAGAAAACTGTGGGACAAGAGGCCCATCATTGAGAACAACAACAGTGTCAGGGAAGTTG
ATACACGAATGGTGTTGCCGCTCGTGCACACTTCCTCCCCTGCGATACATGGGAGAAGAC
GGCTGCTGGTATGGCATGGAAATCAGACCCATTAATGAGAAAGAAGAGAACATGGTAAAG
TCTCTAGCCTCAGCAGGGAGTGGAAAGGTGGACAACTTCACAATGGGTGTCTTGTGTTTG
GCAATCCTCTTTGAAGAGGTGATGAGAGGAAAATTTGGGAAAAAACACATGATTGCAGGG
GTTCTCTTCACGTTTGTGCTCCTCCTCTCAGGGCAAATAACATGGAGAGGCATGGCGCAC
ACACTCATAATGATTGGGTCCAACGCCTCTGACAGAATGGGGATGGGCGTCACTTACCTA
GCTCTAATTGCAACATTTAAAATTCAGCCATTCTTGGCTTTGGGATTCTTCCTGAGGAAA
CTGACATCTAGAGAAAATTTATTGCTGGGAGTTGGGTTGGCCATGGCAGCAACGTTACGA
CTGCCAGAGGACATTGAACAAATGGCGAATGGAATTGCTTTGGGGCTCATGGCTCTTAAA
CTGATAACACAATTTGAAACATACCAACTATGGACGGCATTAGTTTCCCTAACGTGTTCA
AATACAATTTTCACGTTGACTGTTGCCTGGAGAACAGCCACTCTGATTTTAGCCGGAATT
TCGCTTTTGCCAGTGTGCCAGTCTTCGAGCATGAGGAAAACAGATTGGCTCCCAATGACT
GTGGCAGCTATGGGAGTTCCACCCCTACCACTTTTTATTTTCAGTCTGAAAGATACACTC
AAAAGGAGAAGCTGGCCACTGAATGAGGGGGTGATGGCAGTTGGACTTGTGAGCATTCTA
GCTAGTTCTCTCCTTAGGAATGATGTGCCCATGGCTGGACCATTAGTGGCTGGGGGCTTG
CTGATAGCGTGCTACGTCATAACTGGCACGTCAGCAGACCTCACTGTAGAAAAAGCAGCA
GATGTAACATGGGAGGAAGAGGCCGAGCAAACAGGAGTGTCCCACAATTTAATGATCACA
GTTGATGATGATGGAACAATGAGAATAAAAGATGACGAGACTGAGAACATCTTAACAGTG
CTTTTAAAAACAGCACTACTAATAGTATCAGGCATCTTTCCATACTCCATACCCGCAACA
ATGTTGGTCTGGCATACTTGGCAAAAGCAAACCCAAAGATCCGGCGTCCTATGGGACGTA
CCCAGCCCCCCAGAGACACAGAAAGCGGAACTGGAAGAAGGGGTCTATAGGATCAAACAG
CAAGGAATTTTTGGGAAAACCCAAGTGGGGGTTGGAGTACAGAAAGAAGGAGTTTTCCAC
ACCATGTGGCACGTCACAAGAGGGGCAGTGTTGACACACAATGGGAAAAGACTGGAACCA
AACTGGGCTAGCGTGAAAAAAGATCTGATTTCATACGGAGGAGGATGGAGATTGAGTGCA
CAATGGCAAAAGGGGGAGGAGGTGCAGGTTATTGCCGTAGAGCCTGGGAAGAACCCAAAG
AACTTTCAAACCATGCCAGGCATTTTTCAGACAACAACAGGGGAAATAGGAGCAATTGCA
CTGGATTTCAAGCCTGGAACTTCAGGATCTCCCATCATAAACAGAGAGGGAAAGGTAGTG
GGACTGTATGGCAATGGAGTGGTTACAAAGAATGGAGGCTATGTTAGTGGAATAGCGCAA
ACAAATGCAGAACCAGATGGACCGACACCAGAGTTGGAAGAAGAGATGTTCAAAAAGCGA
AATCTAACCATAATGGATCTTCATCCTGGGTCAGGAAAGACGCGGAAATATCTTCCAGCT
ATTGTTAGAGAGGCAATCAAGAGACGCTTAAGGACTCTAATTTTGGCACCAACAAGGGTA
GTTGCAGCTGAGATGGAAGAAGCAATGAAAGGGCTCCCAATAAGGTATCAAACAACTGCA
ACAAAATCTGAACACACAGGAAGAGAGATTGTTGATCTAATGTGTCACGCAACGTTCACA
ATGCGCTTGCTGTCACCAGTCAGGGTTCCAAACTACAACTTGATAATAATGGATGAGGCT
CATTTCACAGACCCAGCCAGTATAGCGGCTAGAGGGTACATATCAACTCGTGTAGGAATG
GGAGAGGCAGCCGCAATTTTCATGACAGCAACACCCCCTGGAACAGCTGATGCCTTTCCT
CAGAGCAACGCTCCAATTCAAGATGAAGAGAGAGACATACCGGAACGCTCATGGAATTCA
GGCAATGAATGGATTACTGACTTTGTTGGGAAGACAGTGTGGTTTGTCCCTAGCATCAAA
GCCGGAAATGTCATAGCAAACTGTTTGCGGAAAAATGGAAAAAAGGTCATTCAACTCAGC
AGGAAGACCTTTGACACAGAATATCAAAAGACCAAACTGAATGATTGGGACTTTGTGGTG
ACAACAGACATTTCAGAAATGGGAGCCAATTTCATAGCAGATAGAGTGATCGACCCAAGA
AGATGTCTCAAGCCGGTGATTTTGACAGATGGACCCGAGCGGGTGATCCTGGCTGGACCA
ATGCCAGTCACCGTAGCGAGCGCTGCGCAAAGGAGAGGGAGAGTTGGCAGGAACCCACAA
AAAGAAAATGACCAGTACATATTCATGGGCCAGCCTCTCAACAAAGATGAAGACCATGCT
CACTGGACAGAAGCAAAAATGCTGCTGGACAACATCAACACACCAGAAGGGATTATACCA
GCTCTCTTTGAACCAGAAAGGGAGAAGTCAGCCGCCATAGACGGCGAATACCGCCTGAAG
GGTGAGTCCAGGAAGACTTTCGTGGAACTCATGAGGAGGGGTGACCTCCCAGTTTGGCTA
GCCCATAAAGTAGCATCAGAAGGGATCAAATATACAGATAGAAAATGGTGCTTTGATGGA
GAACGTAATAATCAAATTTTAGAGGAGAATATGGATGTGGAAATCTGGACAAAGGAAGGA
GAAAAGAAAAAACTGAGACCTAGGTGGCTCGATGCCCGCACTTATTCAGATCCTTTAGCA
CTCAAGGAATTCAAGGATTTTGCAGCTGGCAGAAAGTCAATCGCCCTTGATCTTGTGACA
GAAATAGGAAGAGTGCCTTCACACTTAGCCCACAGAACGAGAAACGCCCTGGACAATTTG
GTGATGCTGCACACGTCAGAACATGGCGGTAGGGCCTACAGGCATGCAGTGGAGGAACTA
CCAGAAACGATGGAAACACTCTTACTCCTGGGACTGATGATCTTGTTAACAGGTGGAGCA
ATGCTCTTCTTGATATCAGGTAAAGGGATTGGAAAGACTTCAATAGGACTCATTTGTGTA
ATTGCTTCCAGCGGCATGTTATGGATGGCTGATGTCCCACTCCAATGGATCGCGTCGGCT
ATAGTCCTGGAGTTTTTTATGATGGTGTTGCTCATACCAGAACCAGAAAAGCAGAGAACT
CCCCAAGACAACCAACTCGCATATGTCGTGATAGGCATACTTACATTGGCTGCAATAGTA
GCGGCCAATGAAATGGGACTGTTGGAAACTACAAAGAGAGATTTAGGAATGTCTAAAGAA
CCAGGTGTTGTTTCTCCAACCAGCTATTTGGATGTGGACTTGCACCCAGCATCAGCCTGG
ACATTGTACGCCGTGGCCACAACAGTAATAACACCAATGTTGAGACACACCATAGAGAAT
TCCACAGCAAATGTGTCCCTGGCAGCCATAGCTAACCAGGCAGTGGTCCTGATGGGTTTA
GACAAAGGATGGCCGATATCGAAAATGGACTTGGGCGTACCACTATTGGCACTGGGTTGC
TATTCACAAGTGAACCCACTAACTCTTATAGCGGCAGTACTTTTGCTAGTCACACATTAT
GCAATTATAGGTCCAGGATTGCAGGCAAAAGCCACTCGTGAAGCTCAGAAAAGGACAGCT
GCTGGAATAATGAAGAATCCAACGGTGGATGGAATAATGACAATAGACCTAGATCCTGTA
ATATATGATTCAAAATTTGAAAAGCAACTAGGACAGGTTATGCTCCTGGTTCTGTGTGCA
GTTCAACTTTTGTTAATGAGAACATCATGGGCCTTGTGTGAAGTTCTAACCCTAGCCACA
GGACCAATAACAACACTCTGGGAAGGATCACCTGGGAAGTTCTGGAACACCACGATAGCT
GTTTCCATGGCGAACATCTTTAGAGGGAGCTATTTAGCAGGAGCTGGGCTTGCTCTTTCT
ATCATGAAATCAGTTGGAACAGGAAAGAGAGGAACAGGGTCACAAGGTGAAACCTTAGGA
GAAAAGTGGAAAAAGAAATTAAATCAGTTATCCCGGAAAGAGTTTGACCTTTACAAGAAA
TCCGGAATCACCGAAGTGGATAGAACAGAAGCCAAAGAAGGGTTAAAAAGAGGAGAAATA
ACACACCATGCCGTGTCCAGAGGCAGCGCAAAACTTCAATGGTTCGTGGAGAGAAACATG
GTCATTCCCGAAGGAAGAGTCATAGACTTAGGCTGTGGAAGAGGAGGCTGGTCATATTAC
TGTGCAGGACTGAAAAAAGTTACAGAAGTGCGAGGATACACAAAAGGCGGCCCAGGACAC
GAAGAACCAGTACCTATGTCTACATACGGATGGAACATAGTCAAGTTAATGAGTGGAAAG
GATGTTTTTTATCTGCCACCTGAAAAGTGTGATACCCTATTGTGTGACATTGGAGAATCT
TCACCAAGCCCAACAGTGGAAGAAAGCAGAACCATAAGAGTCTTGAAGATGGTTGAACCA
TGGCTAAAAAACAACCAGTTTTGCATTAAAGTATTGAACCCATACATGCCAACTGTGATT
GAGCACTTAGAAAGACTACAAAGGAAACATGGAGGAATGCTTGTGAGAAATCCACTCTCA
CGAAACTCCACGCACGAAATGTATTGGATATCCAATGGTACAGGCAACATCGTCTCTTCA
GTCAACATGGTATCCAGATTGCTACTGAACAGATTCACAATGACACACAGGAGACCCACC
ATAGAGAAAGATGTGGATTTAGGAGCAGGAACCCGACATGTCAATGCGGAACCAGAAACA
CCCAACATGGATGTCATTGGGGAAAGAATAAAAAGGATCAAAGAGGAGCATAGTTCAACA
TGGCACTATGATGATGAAAATCCTTACAAAACGTGGGCTTACCATGGATCCTATGAAGTA
AAAGCCACAGGCTCAGCCTCCTCCATGATAAATGGAGTCGTGAAACTCCTCACAAAACCA
TGGGATGTGGTGCCCATGGTGACACAGATGGCAATGACAGATACAACTCCATTTGGCCAG
CAAAGAGTTTTTAAAGAGAAAGTGGACACCAGGACACCTAGGCCCATGCCAGGAACAAGA
AAGGTTATGGAGATCACAGCGGAGTGGCTTTGGAGGACCCTGGGAAGGAACAAAAGACCC
AGATTATGCACAAGGGAGGAGTTCACAAAGAAGGTCAGAACCAACGCAGCTATGGGCGCT
GTCTTCACAGAAGAGAACCAATGGGACAGTGCGAGAGCTGCTGTTGAGGACGAAGAATTT
TGGAAACTTGTGGACAGAGAACGTGAACTCCACAAACTGGGCAAGTGTGGAAGCTGCGTT
TACAACATGATGGGCAAGAGAGAGAAAAAACTTGGAGAGTTTGGTAAAGCAAAAGGCAGT
AGGGCTATATGGTACATGTGGTTGGGAGCCAGGTACCTTGAGTTCGAGGCGCTCGGATTC
CTCAATGAAGACCACTGGTTCTCGCGTGAAAACTCTTACAGTGGAGTAGAAGGAGAAGGA
CTGCACAAGCTGGGATACATCTTGAGAGATATTTCCAAGATACCCGGAGGAGCCATGTAT
GCTGATGACACAGCCGGTTGGGACACAAGAATAACAGAAGATGACCTGCACAATGAGGAA
AAAATCACACAGCAGATGGACCCTGAACACAGGCAGCTAGCGAACGCTATATTCAAGCTC
ACATACCAAAACAAAGTGGTCAAAGTCCAACGACCAACTCCAAAGGGCACGGTAATGGAC
ATCATATCTAGGAAAGACCAAAGAGGCAGTGGACAGGTGGGAACTTATGGTCTGAACACA
TTCACCAACATGGAAGCCCAGCTAATCAGACAAATGGAAGGAGAAGGCGTGTTGTCAAAG
GCAGACCTCGAGAACCCCCATCCGCTAGAGAAGAAAATTACACAATGGTTGGAAACTAAA
GGAGTGGAGAGGTTAAAAAGAATGGCCATCAGCGGGGATGATTGCGTAGTGAAACCAATC
GACGACAGATTCGCCAATGCCCTGCTTGCCCTGAACGATATGGGAAAGGTTAGGAAGGAC
ATACCTCAATGGCAGCCATCAAAGGGATGGCATGATTGGCAACAGGTCCCTTTCTGCTCC
CACCACTTTCATGAATTGATCATGAAAGATGGAAGAAAGTTGGTAGTTCCCTGCAGACCC
CAGGACGAACTAATAGGAAGAGCGAGAATCTCTCAAGGAGCAGGATGGAGCCTTAGAGAA
ACTGCATGTCTAGGGAAAGCCTACGCTCAAATGTGGACTCTCATGTATTTTCACAGAAGA
GATCTTAGACTAGCATCCAACGCCATATGTTCAGCAGTACCAGTCCATTGGGTCCCCACG
AGCAGAACGACATGGTCTATTCATGCTCACCATCAGTGGATGACTACAGAAGACATGCTT
ACTGTCTGGAACAGGGTGTGGATAGAGGACAATCCATGGATGGAAGACAAAACTCCAGTC
ACAACGTGGGAAGATGTTCCATATCTAGGAAAGAGAGAAGACCAATGGTGCGGATCACTC
ATAGGTCTCACTTCCAGAGCAACCTGGGCCCAGAACATACTCACAGCAATCCAACAGGTG
AGAAGCCTCATAGGCAATGAAGAGTTTCTGGACTACATGCCTTCGATGAAGAGATTCAGG
AAGGAGGAGGAGTCAGAGGGAGCCATTTGGTAA

# Drug_Target_10_General_Function:
Involved in nucleic acid binding

# Drug_Target_10_General_References:
2345967	Osatomi K, Sumiyoshi H: Complete nucleotide sequence of dengue type 3 virus genome RNA. Virology. 1990 Jun;176(2):643-7.

# Drug_Target_10_HGNC_ID:
Not Available

# Drug_Target_10_HPRD_ID:
Not Available

# Drug_Target_10_ID:
4783

# Drug_Target_10_Locus:
Not Available

# Drug_Target_10_Molecular_Weight:
378068

# Drug_Target_10_Name:
Genome polyprotein

# Drug_Target_10_Number_of_Residues:
3390

# Drug_Target_10_PDB_ID:
1UZG

# Drug_Target_10_Pathway:
Not Available

# Drug_Target_10_Pfam_Domain_Function:
PF00271	Helicase_C
PF00869	Flavi_glycoprot
PF00948	Flavi_NS1
PF00949	Peptidase_S7
PF00972	Flavi_NS5
PF01002	Flavi_NS2B
PF01003	Flavi_capsid
PF01004	Flavi_M
PF01005	Flavi_NS2A
PF01349	Flavi_NS4B
PF01350	Flavi_NS4A
PF01570	Flavi_propep
PF01728	FtsJ
PF02832	Flavi_glycop_C
PF07652	Flavi_DEAD

# Drug_Target_10_Protein_Sequence:
>Genome polyprotein
MNNQRKKTGKPSINMLKRVRNRVSTGSQLAKRFSRGLLNGQGPMKLVMAFIAFLRFLAIP
PTAGVLARWGTFKKSGAIKVLKGFKKEISNMLSIINKRKKTSLCLMMMLPATLAFHLTSR
DGEPRMIVGKNERGKSLLFKTASGINMCTLIAMDLGEMCDDTVTYKCPHITEVEPEDIDC
WCNLTSTWVTYGTCNQAGEHRRDKRSVALAPHVGMGLDTRTQTWMSAEGAWRQVEKVETW
ALRHPGFTILALFLAHYIGTSLTQKVVIFILLMLVTPSMTMRCVGVGNRDFVEGLSGATW
VDVVLEHGGCVTTMAKNKPTLDIELQKTEATQLATLRKLCIEGKITNITTDSRCPTQGEA
ILPEEQDQNYVCKHTYVDRGWGNGCGLFGKGSLVTCAKFQCLESIEGKVVQHENLKYTVI
ITVHTGDQHQVGNETQGVTAEITSQASTAEAILPEYGTLGLECSPRTGLDFNEMILLTMK
NKAWMVHRQWFFDLPLPWTSGATTKTPTWNRKELLVTFKNAHAKKQEVVVLGSQEGAMHT
ALTGATEIQTSGGTSIFAGHLKCRLKMDKLKLKGMSYAMCLNTFVLKKEVSETQHGTILI
KVEYKGEDAPCKIPFSTEDGQGKAHNGRLITANPVVTKKEEPVNIEAEPPFGESNIVIGI
GDKALKINWYRKGSSIGKMFEATARGARRMAILGDTAWDFGSVGGVLNSLGKMVHQIFGS
AYTALFSGVSWIMKIGIGVLLTWIGLNSKNTSMSFSCIAIGIITLYLGVVVQADMGCVIN
WKGKELKCGSGIFVTNEVHTWTEQYKFQADSPKRVATAIAGAWENGVCGIRSTTRMENLL
WKQIANELNYILWENDIKLTVVVGDITGVLEQGKRTLTPQPMELKYSWKTWGLAKIVTAE
TQNSSFIIDGPSTPECPSASRAWNVWEVEDYGFGVFTTNIWLKLREVYTQLCDHRLMSAA
VKDERAVHADMGYWIESQKNGSWKLEKASLIEVKTCTWPKSHTLWSNGVLESDMIIPKSL
AGPISQHNHRPGYHTQTAGPWHLGKLELDFNYCEGTTVVISENCGTRGPSLRTTTVSGKL
IHEWCCRSCTLPPLRYMGEDGCWYGMEIRPINEKEENMVKSLASAGSGKVDNFTMGVLCL
AILFEEVMRGKFGKKHMIAGVLFTFVLLLSGQITWRGMAHTLIMIGSNASDRMGMGVTYL
ALIATFKIQPFLALGFFLRKLTSRENLLLGVGLAMAATLRLPEDIEQMANGIALGLMALK
LITQFETYQLWTALVSLTCSNTIFTLTVAWRTATLILAGISLLPVCQSSSMRKTDWLPMT
VAAMGVPPLPLFIFSLKDTLKRRSWPLNEGVMAVGLVSILASSLLRNDVPMAGPLVAGGL
LIACYVITGTSADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILTV
LLKTALLIVSGIFPYSIPATMLVWHTWQKQTQRSGVLWDVPSPPETQKAELEEGVYRIKQ
QGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSA
QWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVV
GLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEMFKKRNLTIMDLHPGSGKTRKYLPA
IVREAIKRRLRTLILAPTRVVAAEMEEAMKGLPIRYQTTATKSEHTGREIVDLMCHATFT
MRLLSPVRVPNYNLIIMDEAHFTDPASIAARGYISTRVGMGEAAAIFMTATPPGTADAFP
QSNAPIQDEERDIPERSWNSGNEWITDFVGKTVWFVPSIKAGNVIANCLRKNGKKVIQLS
RKTFDTEYQKTKLNDWDFVVTTDISEMGANFIADRVIDPRRCLKPVILTDGPERVILAGP
MPVTVASAAQRRGRVGRNPQKENDQYIFMGQPLNKDEDHAHWTEAKMLLDNINTPEGIIP
ALFEPEREKSAAIDGEYRLKGESRKTFVELMRRGDLPVWLAHKVASEGIKYTDRKWCFDG
ERNNQILEENMDVEIWTKEGEKKKLRPRWLDARTYSDPLALKEFKDFAAGRKSIALDLVT
EIGRVPSHLAHRTRNALDNLVMLHTSEHGGRAYRHAVEELPETMETLLLLGLMILLTGGA
MLFLISGKGIGKTSIGLICVIASSGMLWMADVPLQWIASAIVLEFFMMVLLIPEPEKQRT
PQDNQLAYVVIGILTLAAIVAANEMGLLETTKRDLGMSKEPGVVSPTSYLDVDLHPASAW
TLYAVATTVITPMLRHTIENSTANVSLAAIANQAVVLMGLDKGWPISKMDLGVPLLALGC
YSQVNPLTLIAAVLLLVTHYAIIGPGLQAKATREAQKRTAAGIMKNPTVDGIMTIDLDPV
IYDSKFEKQLGQVMLLVLCAVQLLLMRTSWALCEVLTLATGPITTLWEGSPGKFWNTTIA
VSMANIFRGSYLAGAGLALSIMKSVGTGKRGTGSQGETLGEKWKKKLNQLSRKEFDLYKK
SGITEVDRTEAKEGLKRGEITHHAVSRGSAKLQWFVERNMVIPEGRVIDLGCGRGGWSYY
CAGLKKVTEVRGYTKGGPGHEEPVPMSTYGWNIVKLMSGKDVFYLPPEKCDTLLCDIGES
SPSPTVEESRTIRVLKMVEPWLKNNQFCIKVLNPYMPTVIEHLERLQRKHGGMLVRNPLS
RNSTHEMYWISNGTGNIVSSVNMVSRLLLNRFTMTHRRPTIEKDVDLGAGTRHVNAEPET
PNMDVIGERIKRIKEEHSSTWHYDDENPYKTWAYHGSYEVKATGSASSMINGVVKLLTKP
WDVVPMVTQMAMTDTTPFGQQRVFKEKVDTRTPRPMPGTRKVMEITAEWLWRTLGRNKRP
RLCTREEFTKKVRTNAAMGAVFTEENQWDSARAAVEDEEFWKLVDRERELHKLGKCGSCV
YNMMGKREKKLGEFGKAKGSRAIWYMWLGARYLEFEALGFLNEDHWFSRENSYSGVEGEG
LHKLGYILRDISKIPGGAMYADDTAGWDTRITEDDLHNEEKITQQMDPEHRQLANAIFKL
TYQNKVVKVQRPTPKGTVMDIISRKDQRGSGQVGTYGLNTFTNMEAQLIRQMEGEGVLSK
ADLENPHPLEKKITQWLETKGVERLKRMAISGDDCVVKPIDDRFANALLALNDMGKVRKD
IPQWQPSKGWHDWQQVPFCSHHFHELIMKDGRKLVVPCRPQDELIGRARISQGAGWSLRE
TACLGKAYAQMWTLMYFHRRDLRLASNAICSAVPVHWVPTSRTTWSIHAHHQWMTTEDML
TVWNRVWIEDNPWMEDKTPVTTWEDVPYLGKREDQWCGSLIGLTSRATWAQNILTAIQQV
RSLIGNEEFLDYMPSMKRFRKEEESEGAIW

# Drug_Target_10_Reaction:
Not Available

# Drug_Target_10_Signals:
None

# Drug_Target_10_Specific_Function:
The small proteins NS2A, NS4A and NS4B are hydrophobic, suggesting a possible membrane-related function. NS5 may play a role in the viral RNA replication. The NS2B/NS3 protease complex processes the viral polyprotein

# Drug_Target_10_SwissProt_ID:
P27915

# Drug_Target_10_SwissProt_Name:
POLG_DEN3P

# Drug_Target_10_Synonyms:
Not Available

# Drug_Target_10_Theoretical_pI:
8.65

# Drug_Target_10_Transmembrane_Regions:
46-67
266-280
724-746
753-771
1156-1175

# Drug_Target_11_Cellular_Location:
Cytoplasmic

# Drug_Target_11_Chromosome_Location:
Not Available

# Drug_Target_11_Drug_References:
Not Available

# Drug_Target_11_Essentiality:
Non-Essential

# Drug_Target_11_GenAtlas_ID:
Not Available

# Drug_Target_11_GenBank_ID_Gene:
Y17980

# Drug_Target_11_GenBank_ID_Protein:
Not Available

# Drug_Target_11_GeneCard_ID:
Not Available

# Drug_Target_11_Gene_Name:
manB

# Drug_Target_11_Gene_Sequence:
>2043 bp
ATGGGGATTGGTGGCGACGACTCCTGGAGCCCGTCAGTATCGGCGGAATTCCTTTTATTG
ATCGTTGAGCTCTCTTTCGTTCTCTTTGCAAGTGACGAGTTCGTGAAAGTGGAAAACGGA
AAATTCGCTCTGAACGGAAAAGAATTCAGATTCATTGGAAGCAACAACTACTACATGCAC
TACAAGAGCAACGGAATGATAGACAGTGTTCTGGAGAGTGCCAGAGACATGGGTATAAAG
GTCCTCAGAATCTGGGGTTTCCTCGACGGGGAGAGTTACTGCAGAGACAAGAACACCTAC
ATGCATCCTGAGCCCGGTGTTTTCGGGGTGCCAGAAGGAATATCGAACGCCCAGAGCGGT
TTCGAAAGACTCGACTACACAGTTGCGAAAGCGAAAGAACTCGGTATAAAACTTGTCATT
GTTCTTGTGAACAACTGGGACGACTTCGGTGGAATGAACCAGTACGTGAGGTGGTTTGGA
GGAACCCATCACGACGATTTCTACAGAGATGAGAAGATCAAAGAAGAGTACAAAAAGTAC
GTCTCCTTTCTCGTAAACCATGTCAATACCTACACGGGAGTTCCTTACAGGGAAGAGCCC
ACCATCATGGCCTGGGAGCTTGCAAACGAACCGCGCTGTGAGACGGACAAATCGGGGAAC
ACGCTCGTTGAGTGGGTGAAGGAGATGAGCTCCTACATAAAGAGTCTGGATCCCAACCAC
CTCGTGGCTGTGGGGGACGAAGGATTCTTCAGCAACTACGAAGGATTCAAACCTTACGGT
GGAGAAGCCGAGTGGGCCTACAACGGCTGGTCCGGTGTTGACTGGAAGAAGCTCCTTTCG
ATAGAGACGGTGGACTTCGGCACGTTCCACCTCTATCCGTCCCACTGGGGTGTCAGTCCA
GAGAACTATGCCCAGTGGGGAGCGAAGTGGATAGAAGACCACATAAAGATCGCAAAAGAG
ATCGGAAAACCCGTTGTTCTGGAAGAATATGGAATTCCAAAGAGTGCGCCAGTTAACAGA
ACGGCCATCTACAGACTCTGGAACGATCTGGTCTACGATCTCGGTGGAGATGGAGCGATG
TTCTGGATGCTCGCGGGAATCGGGGAAGGTTCGGACAGAGACGAGAGAGGGTACTATCCG
GACTACGACGGTTTCAGAATAGTGAACGACGACAGTCCAGAAGCGGAACTGATAAGAGAA
TACGCGAAGCTGTTCAACACAGGTGAAGACATAAGAGAAGACACCTGCTCTTTCATCCTT
CCAAAAGACGGCATGGAGATCAAAAAGACCGTGGAAGTGAGGGCTGGTGTTTTCGACTAC
AGCAACACGTTTGAAAAGTTGTCTGTCAAAGTCGAAGATCTGGTTTTTGAAAATGAGATA
GAGCATCTCGGATACGGAATTTACGGCTTTGATCTCGACACAACCCGGATCCCGGATGGA
GAACATGAAATGTTCCTTGAAGGCCACTTTCAGGGAAAAACGGTGAAAGACTCTATCAAA
GCGAAAGTGGTGAACGAAGCACGGTACGTGCTCGCAGAGGAAGTTGATTTTTCCTCTCCA
GAAGAGGTGAAAAACTGGTGGAACAGCGGAACCTGGCAGGCAGAGTTCGGGTCACCTGAC
ATTGAATGGAACGGTGAGGTGGGAAATGGAGCACTGCAGCTGAACGTGAAACTGCCCGGA
AAGAGCGACTGGGAAGAAGTGAGAGTAGCAAGGAAGTTCGAAAGACTCTCAGAATGTGAG
ATCCTCGAGTACGACATCTACATTCCAAACGTCGAGGGACTCAAGGGAAGGTTGAGGCCG
TACGCGGTTCTGAACCCCGGCTGGGTGAAGATAGGCCTCGACATGAACAACGCGAACGTG
GAAAGTGCGGAGATCATCACTTTCGGCGGAAAAGAGTACAGAAGATTCCATGTAAGAATT
GAGTTCGACAGAACAGCGGGGGTGAAAGAACTTCACATAGGAGTTGTCGGTGATCATCTG
AGGTACGATGGACCGATTTTCATCGATAATGTGAGACTTTATAAAAGAACAGGAGGTATG
TGA

# Drug_Target_11_General_Function:
Involved in catalytic activity

# Drug_Target_11_General_References:
12791255	Boraston AB, Revett TJ, Boraston CM, Nurizzo D, Davies GJ: Structural and thermodynamic dissection of specific mannan recognition by a carbohydrate binding module, TmCBM27. Structure. 2003 Jun;11(6):665-75.

# Drug_Target_11_HGNC_ID:
Not Available

# Drug_Target_11_HPRD_ID:
Not Available

# Drug_Target_11_ID:
4784

# Drug_Target_11_Locus:
Not Available

# Drug_Target_11_Molecular_Weight:
77688

# Drug_Target_11_Name:
Beta-mannosidase

# Drug_Target_11_Number_of_Residues:
680

# Drug_Target_11_PDB_ID:
1OH4

# Drug_Target_11_Pathway:
Not Available

# Drug_Target_11_Pfam_Domain_Function:
PF00150	Cellulase
PF02929	Bgal_small_N

# Drug_Target_11_Protein_Sequence:
>Beta-mannosidase
MGIGGDDSWSPSVSAEFLLLIVELSFVLFASDEFVKVENGKFALNGKEFRFIGSNNYYMH
YKSNGMIDSVLESARDMGIKVLRIWGFLDGESYCRDKNTYMHPEPGVFGVPEGISNAQSG
FERLDYTVAKAKELGIKLVIVLVNNWDDFGGMNQYVRWFGGTHHDDFYRDEKIKEEYKKY
VSFLVNHVNTYTGVPYREEPTIMAWELANEPRCETDKSGNTLVEWVKEMSSYIKSLDPNH
LVAVGDEGFFSNYEGFKPYGGEAEWAYNGWSGVDWKKLLSIETVDFGTFHLYPSHWGVSP
ENYAQWGAKWIEDHIKIAKEIGKPVVLEEYGIPKSAPVNRTAIYRLWNDLVYDLGGDGAM
FWMLAGIGEGSDRDERGYYPDYDGFRIVNDDSPEAELIREYAKLFNTGEDIREDTCSFIL
PKDGMEIKKTVEVRAGVFDYSNTFEKLSVKVEDLVFENEIEHLGYGIYGFDLDTTRIPDG
EHEMFLEGHFQGKTVKDSIKAKVVNEARYVLAEEVDFSSPEEVKNWWNSGTWQAEFGSPD
IEWNGEVGNGALQLNVKLPGKSDWEEVRVARKFERLSECEILEYDIYIPNVEGLKGRLRP
YAVLNPGWVKIGLDMNNANVESAEIITFGGKEYRRFHVRIEFDRTAGVKELHIGVVGDHL
RYDGPIFIDNVRLYKRTGGM

# Drug_Target_11_Reaction:
Not Available

# Drug_Target_11_Signals:
None

# Drug_Target_11_Specific_Function:
Not Available

# Drug_Target_11_SwissProt_ID:
Q9RIK9

# Drug_Target_11_SwissProt_Name:
Q9RIK9_THEMA

# Drug_Target_11_Synonyms:
Not Available

# Drug_Target_11_Theoretical_pI:
4.58

# Drug_Target_11_Transmembrane_Regions:
None

# Drug_Target_12_Cellular_Location:
Not Available

# Drug_Target_12_Chromosome_Location:
Not Available

# Drug_Target_12_Drug_References:
Not Available

# Drug_Target_12_Essentiality:
Non-Essential

# Drug_Target_12_GenAtlas_ID:
IGHG1

# Drug_Target_12_GenBank_ID_Gene:
Not Available

# Drug_Target_12_GenBank_ID_Protein:
Not Available

# Drug_Target_12_GeneCard_ID:
Not Available

# Drug_Target_12_Gene_Name:
IGHG1

# Drug_Target_12_Gene_Sequence:
Not Available

# Drug_Target_12_General_Function:
Not Available

# Drug_Target_12_General_References:
1002129	Dreker L, Schwarz J, Reichel W, Hilschmann N: [Rule of antibody structure. the primary structure of a monoclonal IgG1 immunoglobulin (myeloma protein Nie), I: Purification and characterization of the protein, the L- and H-chains, the cyanogenbromide cleavage products, and the disulfide bridges (author's transl)] Hoppe Seylers Z Physiol Chem. 1976 Nov;357(11):1515-40.
4923144	Gall WE, Edelman GM: The covalent structure of a human gamma G-immunoglobulin. X. Intrachain disulfide bonds. Biochemistry. 1970 Aug 4;9(16):3188-96.
5489771	Cunningham BA, Rutishauser U, Gall WE, Gottlieb PD, Waxdal MJ, Edelman GM: The covalent structure of a human gamma G-immunoglobulin. VII. Amino acid sequence of heavy-chain cyanogen bromide fragments H1-H4. Biochemistry. 1970 Aug 4;9(16):3161-70.
5530842	Rutishauser U, Cunningham BA, Bennett C, Konigsberg WH, Edelman GM: The covalent structure of a human gamma G-immunoglobulin. 8. Amino acid sequence of heavy-chain cyanogen bromide fragments H5-H7. Biochemistry. 1970 Aug 4;9(16):3171-81.
6287432	Ellison JW, Berson BJ, Hood LE: The nucleotide sequence of a human immunoglobulin C gamma1 gene. Nucleic Acids Res. 1982 Jul 10;10(13):4071-9.
6884994	Schmidt WE, Jung HD, Palm W, Hilschmann N: [Three-dimensional structure determination of antibodies. Primary structure of crystallized monoclonal immunoglobulin IgG1 KOL, I] Hoppe Seylers Z Physiol Chem. 1983 Jun;364(6):713-47.
7236608	Deisenhofer J: Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry. 1981 Apr 28;20(9):2361-70.
826475	Ponstingl H, Hilschmann N: [The rule of antibody structure. The primary structure of a monoclonal IgG1 immunoglobulin (myeloma protein Nie). III. The chymotryptic peptides of the H-chain, alignment of the tryptic peptides and discussion of the complete structure] Hoppe Seylers Z Physiol Chem. 1976 Nov;357(11):1571-604.

# Drug_Target_12_HGNC_ID:
HGNC:5525

# Drug_Target_12_HPRD_ID:
Not Available

# Drug_Target_12_ID:
4785

# Drug_Target_12_Locus:
14q32.33

# Drug_Target_12_Molecular_Weight:
36106

# Drug_Target_12_Name:
Ig gamma-1 chain C region

# Drug_Target_12_Number_of_Residues:
330

# Drug_Target_12_PDB_ID:
1HZH

# Drug_Target_12_Pathway:
Not Available

# Drug_Target_12_Pfam_Domain_Function:
PF07654	C1-set

# Drug_Target_12_Protein_Sequence:
>Ig gamma-1 chain C region
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG
PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN
STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE
LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
QQGNVFSCSVMHEALHNHYTQKSLSLSPGK

# Drug_Target_12_Reaction:
Not Available

# Drug_Target_12_Signals:
None

# Drug_Target_12_Specific_Function:
Not Available

# Drug_Target_12_SwissProt_ID:
P01857

# Drug_Target_12_SwissProt_Name:
IGHG1_HUMAN

# Drug_Target_12_Synonyms:
Not Available

# Drug_Target_12_Theoretical_pI:
8.31

# Drug_Target_12_Transmembrane_Regions:
None

# Drug_Target_13_Cellular_Location:
TM:Virion

# Drug_Target_13_Chromosome_Location:
Not Available

# Drug_Target_13_Drug_References:
Not Available

# Drug_Target_13_Essentiality:
Non-Essential

# Drug_Target_13_GenAtlas_ID:
Not Available

# Drug_Target_13_GenBank_ID_Gene:
Not Available

# Drug_Target_13_GenBank_ID_Protein:
Not Available

# Drug_Target_13_GeneCard_ID:
Not Available

# Drug_Target_13_Gene_Name:
env

# Drug_Target_13_Gene_Sequence:
Not Available

# Drug_Target_13_General_Function:
Involved in structural molecule activity

# Drug_Target_13_General_References:
3497350	Franchini G, Gurgo C, Guo HG, Gallo RC, Collalti E, Fargnoli KA, Hall LF, Wong-Staal F, Reitz MS Jr: Sequence of simian immunodeficiency virus and its relationship to the human immunodeficiency viruses. Nature. 1987 Aug 6-12;328(6130):539-43.

# Drug_Target_13_HGNC_ID:
Not Available

# Drug_Target_13_HPRD_ID:
Not Available

# Drug_Target_13_ID:
4787

# Drug_Target_13_Locus:
Not Available

# Drug_Target_13_Molecular_Weight:
101132

# Drug_Target_13_Name:
Envelope glycoprotein gp160

# Drug_Target_13_Number_of_Residues:
881

# Drug_Target_13_PDB_ID:
Not Available

# Drug_Target_13_Pathway:
Not Available

# Drug_Target_13_Pfam_Domain_Function:
PF00516	GP120
PF00517	GP41

# Drug_Target_13_Protein_Sequence:
>Envelope glycoprotein gp160
MGCLGNQLLIAILLLSVYGIYCTQYVTVFYGVPAWRNATIPLFCATKNRDTWGTTQCLPD
NGDYSELALNVTESFDAWENTVTEQAIEDVWQLFETSIKPCVKLSPLCITMRCNKSETDR
WGLTKSSTTITTAAPTSAPVSEKIDMVNETSSCIAQNNCTGLEQEQMISCKFTMTGLKRD
KTKEYNETWYSTDLVCEQGNSTDNESRCYMNHCNTSVIQESCDKHYWDTIRFRYCAPPGY
ALLRCNDTNYSGFMPKCSKVVVSSCTRMMETQTSTWFGFNGTRAENRTYIYWHGRDNRTI
ISLNKYYNLTMKCRRPGNKTVLPVTIMSGLVFHSQPLTDRPKQAWCWFGGKWKDAIKEVK
QTIVKHPRYTGTNNTDKINLTAPGGGDPEVTFMWTNCRGEFLYCKMNWFLNWVEDRDVTT
QRPKERHRRNYVPCHIRQIINTWHKVGKNVYLPPREGDLTCNSTVTSLIANIDWTDGNQT
SITMSAEVAELYRLELGDYKLVEITPIGLAPTDVKRYTTGGTSRNKRGVFVLGFLGFLAT
AGSAMGAASFRLTAQSRTLLAGIVQQQQQLLGVVKRQQELLRLTVWGTKNLQTRVTAIEK
YLEDQAQLNAWGCAFRQVCHTTVPWPNASLTPDWNNDTWQEWERKVDFLEENITALLEEA
QIQQEKNMYELQKLNSWDVFGNWFDLASWIKYIQYGIYVVVGVILLRIVIYIVQMLAKLR
QGYRPVFSSPPSYFQXTHTQQDPALPTREGKEGDGGEGGGNSSWPWQIEYIHFLIRQLIR
LLTWLFSNCRTLLSRAYQILQPILQRLSATLRRIREVLRTELTYLQYGWSYFHEAVQAGW
RSATETLAGAWGDLWETLRRGGRWILAIPRRIRQGLELTLL

# Drug_Target_13_Reaction:
Not Available

# Drug_Target_13_Signals:
1-19

# Drug_Target_13_Specific_Function:
Allows rapid transcytosis of the virus through CD4 negative cells such as simple epithelial monolayers of the intestinal, rectal and endocervical epithelial barriers. Both gp120 and gp41 specifically recognize glycosphingolipids galactosyl-ceramide (GalCer) or 3' sulfo-galactosyl-ceramide (GalS) present in the lipid rafts structures of epithelial cells. Binding to these alternative receptors allows the rapid transcytosis of the virus through the epithelial cells. This transcytotic vesicle-mediated transport of virions from the apical side to the basolateral side of the epithelial cells does not involve infection of the cells themselves (By similarity)

# Drug_Target_13_SwissProt_ID:
P05884

# Drug_Target_13_SwissProt_Name:
ENV_SIVMK

# Drug_Target_13_Synonyms:
Env polyprotein
Envelope glycoprotein gp160 precursor

# Drug_Target_13_Theoretical_pI:
8.40

# Drug_Target_13_Transmembrane_Regions:
697-717

# Drug_Target_14_Cellular_Location:
Not Available

# Drug_Target_14_Chromosome_Location:
Not Available

# Drug_Target_14_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_14_Essentiality:
Non-Essential

# Drug_Target_14_GenAtlas_ID:
Not Available

# Drug_Target_14_GenBank_ID_Gene:
Not Available

# Drug_Target_14_GenBank_ID_Protein:
Not Available

# Drug_Target_14_GeneCard_ID:
Not Available

# Drug_Target_14_Gene_Name:
CHI3L1

# Drug_Target_14_Gene_Sequence:
Not Available

# Drug_Target_14_General_Function:
Not Available

# Drug_Target_14_General_References:
Not Available

# Drug_Target_14_HGNC_ID:
Not Available

# Drug_Target_14_HPRD_ID:
Not Available

# Drug_Target_14_ID:
7113

# Drug_Target_14_Locus:
Not Available

# Drug_Target_14_Molecular_Weight:
Not Available

# Drug_Target_14_Name:
Chitinase-3-like protein 1

# Drug_Target_14_Number_of_Residues:
0

# Drug_Target_14_PDB_ID:
Not Available

# Drug_Target_14_Pathway:
Not Available

# Drug_Target_14_Pfam_Domain_Function:
Not Available

# Drug_Target_14_Protein_Sequence:
Not Available

# Drug_Target_14_Reaction:
Not Available

# Drug_Target_14_Signals:
Not Available

# Drug_Target_14_Specific_Function:
Not Available

# Drug_Target_14_SwissProt_ID:
P36222

# Drug_Target_14_SwissProt_Name:
CH3L1_HUMAN

# Drug_Target_14_Synonyms:
Not Available

# Drug_Target_14_Theoretical_pI:
Not Available

# Drug_Target_14_Transmembrane_Regions:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X54319

# Drug_Target_1_GenBank_ID_Protein:
59304

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
Not Available

# Drug_Target_1_Gene_Sequence:
>1485 bp
ATGCGCTGCATAGGAATATCAAATAGGGACTTTGTGGAAGGAGTGTCAGGAGGGAGTTGG
GTTGACATAGTTTTAGAACATGGAAGTTGTGTGACGACGATGGCAAAAAACAAACCAACA
CTGGACTTTGAACTGATAAAAACAGAAGCCAAACAACCCGCCACCTTAAGGAAGTACTGT
ATAGAGGCTAAACTGACCAACACGACAACAGACTCGCGCTGCCCAACACAAGGGGAACCC
ACCCTGAATGAAGAGCAGGACAAAAGGTTTGTCTGCAAACATTCCATGGTAGACAGAGGA
TGGGGAAATGGATGTGGATTGTTTGGAAAAGGAGGCATCGTGACCTGTGCTATGTTCACA
TGCAAAAAGAACATGGAGGGAAAAATTGTGCAGCCAGAAAACCTGGAATACACTGTCGTG
ATAACACCTCATTCAGGGGAAGAACATGCAGTGGGAAATGACACAGGAAAACATGGTAAA
GAAGTCAAGATAACACCACAGAGCTCCATCACAGAGGCGGAACTGACAGGCTATGGCACT
GTTACGATGGAGTGCTCTCCAAGAACGGGCCTCGACTTCAATGAGATGGTGTTGCTGCAA
ATGGAAGACAAAGCTTGGCTGGTGCACAGACAATGGTTCCTAGACCTACCGTTGCCATGG
CTGCCCGGAGCAGACACACAAGGATCAAATTGGATACAGAAAGAAACACTGGTCACCTTC
AAAAATCCCCATGCGAAAAAACAGGATGTTGTTGTCTTAGGATCCCAAGAGGGGGCCATG
CATACAGCACTCACAGGGGCTACGGAAATCCAGATGTCATCAGGAAACCTGCTGTTCACA
GGACATCTCAAGTGCAGGCTGAGAATGGACAAATTACAACTTAAAGGGATGTCATACTCC
ATGTGCACAGGAAAGTTTAAAATTGTGAAGGAAATAGCAGAAACACAACATGGAACAATA
GTCATTAGAGTACAATATGAAGGAGACGGCTCTCCATGCAAGATCCCCTTTGAGATAATG
GATCTGGAAAAAAGACATGTTTTGGGCCGCCTGATCACAGTCAACCCAATTGTAACAGAA
AAGGACAGTCCAGTCAACATAGAAGCAGAACCTCCATTCGGAGACAGCTACATCATCATA
GGAGTGGAACCAGGACAATTGAAGCTGGACTGGTTCAAGAAAGGAAGTTCCATCGGCCAA
ATGTTTGAGACAACAATGAGGGGAGCGAAAAGAATGGCCATTTTGGGTGACACAGCCTGG
GATTTTGGATCTCTGGGAGGAGTGTTCACATCAATAGGAAAGGCTCTCCACCAGGTTTTT
GGAGCAATCTACGGGGCTGCTTTCAGTGGGGTCTCATGGACTATGAAGATCCTCATAGGA
GTTATCATCACATGGATAGGAATGAACTCACGTAGCACATCACTGTCTGTGTCACTGGTA
TTAGTGGGAATCGTGACACTGTACTTGGGAGTTATGGTGCAGGCC

# Drug_Target_1_General_Function:
Involved in nucleic acid binding

# Drug_Target_1_General_References:
2216784	Chen WB, Maguire T: Nucleotide sequence of the envelope glycoprotein gene of a dengue-2 virus isolated during an epidemic of benign dengue fever in Tonga in 1974. Nucleic Acids Res. 1990 Oct 11;18(19):5889.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2860

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
187443

# Drug_Target_1_Name:
Genome polyprotein

# Drug_Target_1_Number_of_Residues:
1683

# Drug_Target_1_PDB_ID:
1P58

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00869	Flavi_glycoprot
PF00948	Flavi_NS1
PF00949	Peptidase_S7
PF01005	Flavi_NS2A
PF02832	Flavi_glycop_C
PF07652	Flavi_DEAD

# Drug_Target_1_Protein_Sequence:
>Genome polyprotein [Contains: Major envelope protein E; Non-structural protein 1
MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYC
IEAKLTNTTTDSRCPTQGEPTLNEEQDKRFVCKHSMVDRGWGNGCGLFGKGGIVTCAMFT
CKKNMEGKIVQPENLEYTVVITPHSGEEHAVGNDTGKHGKEVKITPQSSITEAELTGYGT
VTMECSPRTGLDFNEMVLLQMEDKAWLVHRQWFLDLPLPWLPGADTQGSNWIQKETLVTF
KNPHAKKQDVVVLGSQEGAMHTALTGATEIQMSSGNLLFTGHLKCRLRMDKLQLKGMSYS
MCTGKFKIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPIVTE
KDSPVNIEAEPPFGDSYIIIGVEPGQLKLDWFKKGSSIGQMFETTMRGAKRMAILGDTAW
DFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVSLV
LVGIVTLYLGVMVQADSGCVVSWKNKELKCGSGIFVTDNVHTWTEQYKFQPESPSKLASA
IQKAHEEGICGIRSVTRLENLMWKQITSELNHILSENEVKLTIMTGDIKGIMQVGKRSLR
PQPTELRYSWKTWGKAKMLSTELHNQTFLIDGPETAECPNTNRAWNSLEVEDYGFGVFTT
NIWLRLREKQDVFCDSKLMSAAIKDNRAVHADMGYWIESALNDTWKIEKASFIEVKSCHW
PKSHTLWSNGVLESEMVIPKNFAGPVSQHNNRPGYYTQTAGPWHLGKLEMDFDFCEGTTV
VVTEDCGNRGPSLRTTTASGKLITEWCCRSCTLPPLRYRGEDGCWYGMEIRPLKEKEENL
VSSLVTAGHGQIDNFSLGILGMALFLEEMLRTRVGTKHAILLVAVSFVTLITGNMSFRDL
GRVMVMVGATMTDDIGMGVTYLALLAAFRVRPTFAAGLLLRKLTSKELMMTTIGIVLLSQ
SSIPETILELTDALALGMMVLKMVRNMEKYQLAVTIMAILCVPNAVILQNAWKVSCTILA
VVSVSPLLLTSSQQKADWIPLALTIKGLNPTAIFLTTLSRTSKKRAGVLWDVPSPPPVGK
AELEDGAYRIKQKGILGYSQIGAGVYKEGTFHTMWHVTRGAVLMHKGKRIEPSWADVKKD
LISYGGGWKLEGEWKEGEEVQVLALEPGKNPRAVQTKPGLFRTNTGTIGAVSLDFSPGTS
GSPIVDKKGKVVGLYGNGVVTRSGAYVSAIAQTEKSIEDNPEIEDDIFRKRRLTIMDLHP
GAGKTKRYLPAIVREAIKRGLRTLILAPTRVVAAEMEEALRGLPIRYQTPAIRAEHTGRE
IVDLMCHATFTMRLLSPIRVPNYNLIIMDEAHFTDPASIAARGYISTRVEMGEAAGIFMT
ATPPGSRDPFPQSNAPIMDEEREIPERSWNSGHEWVTDFKGKTVWFVPSIKTGNDIAACL
RKNGKRVIQLSRKTFDSEYVKTRTNDWDFVVTTDISEMGANFKAERVIDPRRCMKPVILT
DGEERVILAGPMPVTHSSAAQRRGRIGRNPRNENDQYIYMGEPLENDEDCAHWKEAKMLL
DNINTPEGIIPSIFEPEREKVDAIDGEYRLRGEARKTFVDLMRRGDLPVWLAYKVAAEGI
NYADRRWCFDGTRNNQILEENVEVEIWTKEGERKKLKPRWLDARIYSDPLALKEFKEFAA
GRK

# Drug_Target_1_Reaction:
Selective hydrolysis of -Xaa-Xaa!Yaa- bonds in which each of the Xaa can be either Arg or Lys and Yaa can be either Ser or Ala

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Selective hydrolysis of -Xaa-Xaa-|-Yaa- bonds in which each of the Xaa can be either Arg or Lys and Yaa can be either Ser or Ala

# Drug_Target_1_SwissProt_ID:
P27914

# Drug_Target_1_SwissProt_Name:
POLG_DEN2T

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
8.05

# Drug_Target_1_Transmembrane_Regions:
457-470
472-495

# Drug_Target_2_Cellular_Location:
Virion
apical cell membrane
single-pass type II membrane protein (
virion membrane. Cell membrane

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
M11445

# Drug_Target_2_GenBank_ID_Protein:
324416

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
NA

# Drug_Target_2_Gene_Sequence:
>1413 bp
ATGAATCCAAATCAGAAGATTCTATGCACTTCTGCCACTGCTCTCGTAATAGGCACAATT
GCAGTACTCATAGGAATAACGAACTTAGGATTGAACATAGGACTACATCTGAAACCGAGC
TGCAATTGCTCACACTCACAACCCGAAGCAACCAATGCAAGCCAAACAATAATAAATAAC
TATTATAATGACACAAACATCACCCAGATAAGTAATACCAACATTCAGGTAGAGGAAAGG
GCAATTAGAGATTTCAATAACTTGACCAAAGGGCTCTGTACTATAAATTCATGGCACATA
TATGGGAAAGACAATGCGGTGAGAATTGGGGAGGACTCAGATGTTTTAGTCACAAGAGAA
CCCTATGTCTCCTGTGACCCAGATGAGTGCAGGTTCTATGCTCTCAGCCAAGGGACAACA
ATCAGAGGAAAACACTCAAATGGAACAATACACGATAGGTCTCAATATCGTGCCCTGATA
AGCTGGCCATTGTCATCACCGCCCACAGTATACAACAGCAGAGTGGAATGCATTGGATGG
TCAAGTACTAGTTGTCATGATGGCAAAACCAGGATGTCAATATGCATATCAGGCCCGAAC
AATAACGCATCAGCAGTGATCTGGTACAATAGAAGGCCTGTGACAGAAATCAACACATGG
GCCCGAAACATACTAAGGACACAAGAATCTGAATGCGTATGCCACAACGGTGTCTGCCCG
GTAGTGTTCACAGATGGGTCTGCCACTGGACCTGCAGAAACAAGAATATACTATTTTAAA
GAAGGGAAGATCTTAAAATGGGAACCTCTGGCTGGAACTGCTAAGCATATCGAAGAATGC
TCATGCTACGGAGAGCGAGCAGAGATTACTTGCACGTGTAGGGATAATTGGCAAGGCTCA
AATAGACCAGTAATTCGGATAGATCCAGTGGCGATGACACATACTAGTCAGTATATATGT
AGCCCTGTTCTCACAGATAACCCCCGACCGAATGACCCAACTGTAGGTAAGTGTAACGAC
CCTTATCCAGGCAATAACAACAATGGGGTCAAAGGGTTTTCATATCTGGATGGAGTTAAT
ACTTGGCTAGGGAGGACAATAAGCATAGCTTCAAGATCCGGATATGAGATGCTAAAGGTG
CCAAATGCATTGACAGACGATAAGTCAAAGCCCACTCAAGGTCAGACAATCGTCTTAAAC
ACTGACTGGAGTGGTTACAGTGGGTCCTTCATGGACTATTGGGCTGAGGGGGAATGCTAC
CGAGCGTGTTTTTACGTGGAGTTAATACGTGGGAGACCTAAGGAGGATAAAGTGTGGTGG
ACCAGTAATAGTATAGTATCGATGTGTTCCAGCACAGAATTCCTTGGACAATGGGACTGG
CCTGATGGGGCTAAAATAGAGTACTTCCTCTAA

# Drug_Target_2_General_Function:
Not Available

# Drug_Target_2_General_References:
3447170	Baker AT, Varghese JN, Laver WG, Air GM, Colman PM: Three-dimensional structure of neuraminidase of subtype N9 from an avian influenza virus. Proteins. 1987;2(2):111-7.
3660585	Air GM, Webster RG, Colman PM, Laver WG: Distribution of sequence differences in influenza N9 neuraminidase of tern and whale viruses and crystallization of the whale neuraminidase complexed with antibodies. Virology. 1987 Oct;160(2):346-54.
4013081	Air GM, Ritchie LR, Laver WG, Colman PM: Gene and protein sequence of an influenza neuraminidase with hemagglutinin activity. Virology. 1985 Aug;145(1):117-22.
8371267	Bossart-Whitaker P, Carson M, Babu YS, Smith CD, Laver WG, Air GM: Three-dimensional structure of influenza A N9 neuraminidase and its complex with the inhibitor 2-deoxy 2,3-dehydro-N-acetyl neuraminic acid. J Mol Biol. 1993 Aug 20;232(4):1069-83.
9342319	Varghese JN, Colman PM, van Donkelaar A, Blick TJ, Sahasrabudhe A, McKimm-Breschkin JL: Structural evidence for a second sialic acid binding site in avian influenza virus neuraminidases. Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):11808-12.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
3026

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
52469

# Drug_Target_2_Name:
Neuraminidase

# Drug_Target_2_Number_of_Residues:
470

# Drug_Target_2_PDB_ID:
1NMB

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00064	Neur

# Drug_Target_2_Protein_Sequence:
>Neuraminidase
MNPNQKILCTSATALVIGTIAVLIGITNLGLNIGLHLKPSCNCSHSQPEATNASQTIINN
YYNDTNITQISNTNIQVEERAIRDFNNLTKGLCTINSWHIYGKDNAVRIGEDSDVLVTRE
PYVSCDPDECRFYALSQGTTIRGKHSNGTIHDRSQYRALISWPLSSPPTVYNSRVECIGW
SSTSCHDGKTRMSICISGPNNNASAVIWYNRRPVTEINTWARNILRTQESECVCHNGVCP
VVFTDGSATGPAETRIYYFKEGKILKWEPLAGTAKHIEECSCYGERAEITCTCRDNWQGS
NRPVIRIDPVAMTHTSQYICSPVLTDNPRPNDPTVGKCNDPYPGNNNNGVKGFSYLDGVN
TWLGRTISIASRSGYEMLKVPNALTDDKSKPTQGQTIVLNTDWSGYSGSFMDYWAEGECY
RACFYVELIRGRPKEDKVWWTSNSIVSMCSSTEFLGQWDWPDGAKIEYFL

# Drug_Target_2_Reaction:
Hydrolysis of alpha-(2->3)-, alpha-(2->6)-, alpha-(2->8)- glycosidic linkages of terminal sialic acid residues in oligosaccharides, glycoproteins, glycolipids, colominic acid and synthetic substrates ALL_REAC (other) R03491 R04018 R04634 R04650 R05115 R05117 R05996(G) R05998(G) R05999(G) R06012(G) R06147(G) R06253(G) INHIBITOR 2-Deoxy-2,3-dehydro-N-acetylneuraminic acid

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Catalyzes the removal of terminal sialic acid residues from viral and cellular glycoconjugates. Cleaves off the terminal sialic acids on the glycosylated HA during virus budding to facilitate virus release. Additionally helps virus spread through the circulation by further removing sialic acids from the cell surface. These cleavages prevent self-aggregation and ensure the efficient spread of the progeny virus from cell to cell. Otherwise, infection would be limited to one round of replication. Described as a receptor-destroying enzyme because it cleaves a terminal sialic acid from the cellular receptors. May facilitate viral invasion of the upper airways by cleaving the sialic acid moities on the mucin of the airway epithelial cells. Likely to plays a role in the budding process through its association with lipid rafts during intracellular transport. May additionally display a raft-association independent effect on budding. Plays a role in the determination of host range restriction on replication and virulence. Sialidase activity in late endosome/lysosome traffic seems to enhance virus replication

# Drug_Target_2_SwissProt_ID:
P03472

# Drug_Target_2_SwissProt_Name:
NRAM_I75A5

# Drug_Target_2_Synonyms:
EC 3.2.1.18

# Drug_Target_2_Theoretical_pI:
6.57

# Drug_Target_2_Transmembrane_Regions:
7-35

# Drug_Target_3_Cellular_Location:
Membrane
single-pass type I membrane protein

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
SIGLEC7

# Drug_Target_3_GenBank_ID_Gene:
AF170485

# Drug_Target_3_GenBank_ID_Protein:
6466012

# Drug_Target_3_GeneCard_ID:
SIGLEC7

# Drug_Target_3_Gene_Name:
SIGLEC7

# Drug_Target_3_Gene_Sequence:
>1404 bp
ATGCTGCTGCTGCTGCTGCTGCCCCTGCTCTGGGGGAGGGAGAGGGTGGAAGGACAGAAG
AGTAACCGGAAGGATTACTCGCTGACGATGCAGAGTTCCGTGACCGTGCAAGAGGGCATG
TGTGTCCATGTGCGCTGCTCCTTCTCCTACCCAGTGGACAGCCAGACTGACTCTGACCCA
GTTCATGGCTACTGGTTCCGGGCAGGGAATGATATAAGCTGGAAGGCTCCAGTGGCCACA
AACAACCCAGCTTGGGCAGTGCAGGAGGAAACTCGGGACCGATTCCACCTCCTTGGGGAC
CCACAGACCAAAAATTGCACCCTGAGCATCAGAGATGCCAGAATGAGTGATGCGGGGAGA
TACTTCTTTCGTATGGAGAAAGGAAATATAAAATGGAATTATAAATATGACCAGCTCTCT
GTGAACGTGACAGCCTTGACCCACAGGCCCAACATCCTTATCCCCGGTACCCTGGAGTCT
GGCTGCTTCCAGAATCTGACCTGCTCTGTGCCCTGGGCCTGTGAGCAGGGGACGCCCCCT
ATGATCTCCTGGATGGGGACCTCTGTGTCCCCCCTGCACCCCTCCACCACCCGCTCCTCA
GTGCTCACCCTCATCCCACAGCCCCAGCACCACGGCACCAGCCTCACCTGTCAGGTGACC
TTGCCTGGGGCCGGCGTGACCACGAACAGGACCATCCAACTCAATGTGTCCTACCCTCCT
CAGAACTTGACTGTGACTGTCTTCCAAGGAGAAGGCACAGCATCCACAGCTCTGGGGAAC
AGCTCATCTCTTTCAGTCCTAGAGGGCCAGTCTCTGCGCTTGGTCTGTGCTGTTGACAGC
AATCCCCCTGCCAGGCTGAGCTGGACCTGGAGGAGTCTGACCCTGTACCCCTCACAGCCC
TCAAACCCTCTGGTACTGGAGCTGCAAGTGCACCTGGGGGATGAAGGGGAATTCACCTGT
CGAGCTCAGAACTCTCTGGGTTCCCAGCACGTTTCCCTGAACCTCTCCCTGCAACAGGAG
TACACAGGCAAAATGAGGCCTGTATCAGGAGTGTTGCTGGGGGCGGTCGGGGGAGCTGGA
GCCACAGCCCTGGTCTTCCTCTCCTTCTGTGTCATCTTCATTGTAGTGAGGTCCTGCAGG
AAGAAATCGGCAAGGCCAGCAGCGGACGTGGGAGACATAGGCATGAAGGATGCAAACACC
ATCAGGGGCTCAGCCTCTCAGGGTAACCTGACTGAGTCCTGGGCAGATGATAACCCCCGA
CACCATGGCCTGGCTGCCCACTCCTCAGGGGAGGAAAGAGAGATCCAGTATGCACCCCTC
AGCTTTCATAAGGGGGAGCCTCAGGACCTATCAGGTCAAGAAGCCACCAACAATGAGTAC
TCAGAGATCAAGATCCCCAAGTAA

# Drug_Target_3_General_Function:
Involved in sugar binding activity

# Drug_Target_3_General_References:
10499918	Falco M, Biassoni R, Bottino C, Vitale M, Sivori S, Augugliaro R, Moretta L, Moretta A: Identification and molecular cloning of p75/AIRM1, a novel member of the sialoadhesin family that functions as an inhibitory receptor in human natural killer cells. J Exp Med. 1999 Sep 20;190(6):793-802.
10567377	Nicoll G, Ni J, Liu D, Klenerman P, Munday J, Dubock S, Mattei MG, Crocker PR: Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes. J Biol Chem. 1999 Nov 26;274(48):34089-95.
10611343	Vitale C, Romagnani C, Falco M, Ponte M, Vitale M, Moretta A, Bacigalupo A, Moretta L, Mingari MC: Engagement of p75/AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cells. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15091-6.
10764831	Angata T, Varki A: Siglec-7: a sialic acid-binding lectin of the immunoglobulin superfamily. Glycobiology. 2000 Apr;10(4):431-8.
11389909	Ito A, Handa K, Withers DA, Satoh M, Hakomori S: Binding specificity of siglec7 to disialogangliosides of renal cell carcinoma: possible role of disialogangliosides in tumor progression. FEBS Lett. 2001 Jun 1;498(1):116-20.

# Drug_Target_3_HGNC_ID:
HGNC:10876

# Drug_Target_3_HPRD_ID:
05102

# Drug_Target_3_ID:
2998

# Drug_Target_3_Locus:
19q13.3

# Drug_Target_3_Molecular_Weight:
51143

# Drug_Target_3_Name:
Sialic acid-binding Ig-like lectin 7

# Drug_Target_3_Number_of_Residues:
467

# Drug_Target_3_PDB_ID:
1NKO

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00047	ig
PF07686	V-set
PF08205	C2-set_2

# Drug_Target_3_Protein_Sequence:
>Sialic acid-binding Ig-like lectin 7 precursor
MLLLLLLPLLWGRERVEGQKSNRKDYSLTMQSSVTVQEGMCVHVRCSFSYPVDSQTDSDP
VHGYWFRAGNDISWKAPVATNNPAWAVQEETRDRFHLLGDPQTKNCTLSIRDARMSDAGR
YFFRMEKGNIKWNYKYDQLSVNVTALTHRPNILIPGTLESGCFQNLTCSVPWACEQGTPP
MISWMGTSVSPLHPSTTRSSVLTLIPQPQHHGTSLTCQVTLPGAGVTTNRTIQLNVSYPP
QNLTVTVFQGEGTASTALGNSSSLSVLEGQSLRLVCAVDSNPPARLSWTWRSLTLYPSQP
SNPLVLELQVHLGDEGEFTCRAQNSLGSQHVSLNLSLQQEYTGKMRPVSGVLLGAVGGAG
ATALVFLSFCVIFIVVRSCRKKSARPAADVGDIGMKDANTIRGSASQGNLTESWADDNPR
HHGLAAHSSGEEREIQYAPLSFHKGEPQDLSGQEATNNEYSEIKIPK

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
1-18

# Drug_Target_3_Specific_Function:
Putative adhesion molecule that mediates sialic-acid dependent binding to cells. Preferentially binds to alpha2,3 and alpha2,6-linked sialic acid. Also binds disialogangliosides (disialogalactosyl globoside, disialyl lactotetraosylceramide and disialyl GalNAc lactotetraoslylceramide). The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. In the immune response, may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. Mediates inhibition of natural killer cells cytotoxicity. May play a role in hemopoiesis. Inhibits differentiation of CD34+ cell precursors towards myelomonocytic cell lineage and proliferation of leukemic myeloid cells (in vitro)

# Drug_Target_3_SwissProt_ID:
Q9Y286

# Drug_Target_3_SwissProt_Name:
SIGL7_HUMAN

# Drug_Target_3_Synonyms:
AIRM-1
Adhesion inhibitory receptor molecule 1
CD328 antigen
CDw328
D-siglec
QA79 membrane protein
Sialic acid-binding Ig-like lectin 7 precursor
Siglec-7
p75

# Drug_Target_3_Theoretical_pI:
7.32

# Drug_Target_3_Transmembrane_Regions:
354-376

# Drug_Target_4_Cellular_Location:
Note=Localized in granules from where it may be secreted or transported to other locations in the ce

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
CLC

# Drug_Target_4_GenBank_ID_Gene:
L01664

# Drug_Target_4_GenBank_ID_Protein:
187274

# Drug_Target_4_GeneCard_ID:
CLC

# Drug_Target_4_Gene_Name:
CLC

# Drug_Target_4_Gene_Sequence:
>429 bp
ATGTCCCTGCTACCCGTGCCATACACAGAGGCTGCCTCTTTGTCTACTGGTTCTACTGTG
ACAATCAAAGGGCGACCACTTGTCTGTTTCTTGAATGAACCATATCTGCAGGTGGATTTC
CACACTGAGATGAAGGAGGAATCAGACATTGTCTTCCATTTCCAAGTGTGCTTTGGTCGT
CGTGTGGTCATGAACAGCCGTGAGTATGGGGCCTGGAAGCAGCAGGTGGAATCCAAGAAC
ATGCCCTTTCAGGATGGCCAAGAATTTGAACTGAGCATCTCAGTGCTGCCAGATAAGTAC
CAGGTAATGGTCAATGGCCAATCCTCTTACACCTTTGACCATAGAATCAAGCCTGAGGCT
GTGAAGATGGTGCAAGTGTGGAGAGATATCTCCCTGACCAAATTTAATGTCAGCTATTTA
AAGAGATAA

# Drug_Target_4_General_Function:
Involved in sugar binding

# Drug_Target_4_General_References:
10529229	Swaminathan GJ, Leonidas DD, Savage MP, Ackerman SJ, Acharya KR: Selective recognition of mannose by the human eosinophil Charcot-Leyden crystal protein (galectin-10): a crystallographic study at 1.8 A resolution. Biochemistry. 1999 Oct 19;38(42):13837-43.
1577491	Mastrianni DM, Eddy RL, Rosenberg HF, Corrette SE, Shows TB, Tenen DG, Ackerman SJ: Localization of the human eosinophil Charcot-Leyden crystal protein (lysophospholipase) gene (CLC) to chromosome 19 and the human ribonuclease 2 (eosinophil-derived neurotoxin) and ribonuclease 3 (eosinophil cationic protein) genes (RNS2 and RNS3) to chromosome 14. Genomics. 1992 May;13(1):240-2.
8419478	Ackerman SJ, Corrette SE, Rosenberg HF, Bennett JC, Mastrianni DM, Nicholson-Weller A, Weller PF, Chin DT, Tenen DG: Molecular cloning and characterization of human eosinophil Charcot-Leyden crystal protein (lysophospholipase). Similarities to IgE binding proteins and the S-type animal lectin superfamily. J Immunol. 1993 Jan 15;150(2):456-68.
8747464	Leonidas DD, Elbert BL, Zhou Z, Leffler H, Ackerman SJ, Acharya KR: Crystal structure of human Charcot-Leyden crystal protein, an eosinophil lysophospholipase, identifies it as a new member of the carbohydrate-binding family of galectins. Structure. 1995 Dec 15;3(12):1379-93.
9119387	Dyer KD, Handen JS, Rosenberg HF: The genomic structure of the human Charcot-Leyden crystal protein gene is analogous to those of the galectin genes. Genomics. 1997 Mar 1;40(2):217-21.

# Drug_Target_4_HGNC_ID:
HGNC:2014

# Drug_Target_4_HPRD_ID:
08351

# Drug_Target_4_ID:
3437

# Drug_Target_4_Locus:
19q13.1

# Drug_Target_4_Molecular_Weight:
16481

# Drug_Target_4_Name:
Eosinophil lysophospholipase

# Drug_Target_4_Number_of_Residues:
142

# Drug_Target_4_PDB_ID:
1QKQ

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00337	Gal-bind_lectin

# Drug_Target_4_Protein_Sequence:
>Eosinophil lysophospholipase
MSLLPVPYTEAASLSTGSTVTIKGRPLVCFLNEPYLQVDFHTEMKEESDIVFHFQVCFGR
RVVMNSREYGAWKQQVESKNMPFQDGQEFELSISVLPDKYQVMVNGQSSYTFDHRIKPEA
VKMVQVWRDISLTKFNVSYLKR

# Drug_Target_4_Reaction:
2-lysophosphatidylcholine + H2O = glycerophosphocholine + a carboxylate ALL_REAC (other) R01309 R02744 R02746 R02747 R03416 R03417 R04499

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
May have both lysophospholipase and carbohydrate-binding activities

# Drug_Target_4_SwissProt_ID:
Q05315

# Drug_Target_4_SwissProt_Name:
LPPL_HUMAN

# Drug_Target_4_Synonyms:
CLC
Charcot-Leyden crystal protein
EC 3.1.1.5
Galectin-10
Lysolecithin acylhydrolase

# Drug_Target_4_Theoretical_pI:
7.50

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Cytoplasmic

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
Not Available

# Drug_Target_5_GenBank_ID_Gene:
X82179

# Drug_Target_5_GenBank_ID_Protein:
14594858

# Drug_Target_5_GeneCard_ID:
Not Available

# Drug_Target_5_Gene_Name:
manA

# Drug_Target_5_Gene_Sequence:
>1272 bp
ATGAAAACTATTACCACTGCACGCCTTCCATGGGCTGCGCAGAGCTTTGCCTTGGGCATT
TGCCTGATAGCGCTGTTGGGTTGTAATCACGCCGCTAATAAATCATCGGCATCCAGGGCA
GATGTCAAACCTGTTACGGTCAAACTGGTCGATTCCCAGGCGACCATGGAAACCCGTTCC
CTGTTTGCGTTTATGCAGGAGCAGCGCAGACATTCCATTATGTTTGGGCACCAGCACGAA
ACAACCCAGGGACTCACTATTACCCGCACAGATGGTACCCAATCCGATACCTTTAATGCC
GTTGGTGATTTTGCAGCGGTCTATGGTTGGGACACGCTGTCTATTGTTGCCCCTAAAGCG
GAGGGCGATATTGTCGCCCAAGTAAAAAAGGCTTATGCGCGCGGGGGCATCATTACGGTG
AGCTCGCATTTTGATAATCCAAAAACCGATACCCAAAAGGGCGTATGGCCCGTTGGCACT
TCCTGGGATCAAACCCCGGCTGTTGTGGATTCCCTGCCTGGAGGCGCCTATAACCCGGTA
TTAAATGGCTATCTCGACCAGGTGGCCGAGTGGGCCAATAACCTGAAAGACGAGCAGGGG
CGGCTGATACCGGTCATCTTTCGCCTGTACCACGAAAATACCGGCAGTTGGTTCTGGTGG
GGAGATAAGCAATCAACCCCTGAACAATACAAGCAATTGTTCCGCTATTCCGTCGAGTAT
TTGCGCGATGTGAAAGGTGTGCGCAATTTCCTGTATGCCTATTCGCCCAACAACTTTTGG
GACGTGACCGAGGCCAATTACCTGGAGCGTTATCCGGGGGATGAGTGGGTGGATGTACTG
GGATTTGATACCTATGGCCCGGTGGCGGACAACGCTGACTGGTTCCGCAATGTGGTGGCC
AATGCGGCCTTGGTTGCCCGCATGGCGGAAGCGCGGGGCAAAATACCGGTGATCTCCGAG
ATAGGTATACGCGCTCCCGACATTGAAGCCGGGCTCTATGATAACCAGTGGTATCGCAAG
CTTATCTCCGGCCTCAAGGCCGATCCGGATGCACGCGAGATTGCCTTCCTGCTGGTATGG
CGCAATGCCCCGCAGGGAGTTCCTGGCCCCAATGGCACCCAGGTTCCCCATTATTGGGTG
CCTGCTAACCGCCCGGAGAATATCAACAATGGCACCCTGGAGGACTTCCAGGCCTTTTAT
GCCGATGAATTCACAGCGTTCAATCGCGACATCGAGCAGGTCTATCAGCGTCCGACCCTG
ATAGTTAAATAG

# Drug_Target_5_General_Function:
Involved in mannan endo-1,4-beta-mannosidase activity

# Drug_Target_5_General_References:
7848261	Braithwaite KL, Black GW, Hazlewood GP, Ali BR, Gilbert HJ: A non-modular endo-beta-1,4-mannanase from Pseudomonas fluorescens subspecies cellulosa. Biochem J. 1995 Feb 1;305 ( Pt 3):1005-10.

# Drug_Target_5_HGNC_ID:
Not Available

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
3480

# Drug_Target_5_Locus:
Not Available

# Drug_Target_5_Molecular_Weight:
47488

# Drug_Target_5_Name:
Mannan endo-1,4-beta-mannosidase

# Drug_Target_5_Number_of_Residues:
423

# Drug_Target_5_PDB_ID:
1R7O

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF02156	Glyco_hydro_26

# Drug_Target_5_Protein_Sequence:
>Mannan endo-1,4-beta-mannosidase precursor
MKTITTARLPWAAQSFALGICLIALLGCNHAANKSSASRADVKPVTVKLVDSQATMETRS
LFAFMQEQRRHSIMFGHQHETTQGLTITRTDGTQSDTFNAVGDFAAVYGWDTLSIVAPKA
EGDIVAQVKKAYARGGIITVSSHFDNPKTDTQKGVWPVGTSWDQTPAVVDSLPGGAYNPV
LNGYLDQVAEWANNLKDEQGRLIPVIFRLYHENTGSWFWWGDKQSTPEQYKQLFRYSVEY
LRDVKGVRNFLYAYSPNNFWDVTEANYLERYPGDEWVDVLGFDTYGPVADNADWFRNVVA
NAALVARMAEARGKIPVISEIGIRAPDIEAGLYDNQWYRKLISGLKADPDAREIAFLLVW
RNAPQGVPGPNGTQVPHYWVPANRPENINNGTLEDFQAFYADEFTAFNRDIEQVYQRPTL
IVK

# Drug_Target_5_Reaction:
Random hydrolysis of 1,4-beta-D-mannosidic linkages in mannans, galactomannans and glucomannans ALL_REAC (other) R01332 R06207(G) REFERENCE 1 AUTHORS Eriksson, A.F.V. TITLE Purification and characterisation of a fungal beta-mannanase. JOURNAL Acta Chem. Scand. 22 (1968) 1924-1934. ORGANISM Aspergillus niger REFERENCE 2 AUTHORS Reese, E.T. TITLE beta-Mannanases of fungi. JOURNAL Can. J. Microbiol. 11 (1965) 167-183. ORGANISM Paecilomyces variotii, Penicillium funiculosum, Penicillium wortmanni, Penicillium verruculosum, Penicillium ochro-chloron, Fusicoccum sp., Aspergillus luchuensis, Aspergillus giganteus, Paecilomyces variotii

# Drug_Target_5_Signals:
1-31

# Drug_Target_5_Specific_Function:
Hydrolyzes mannan and galactomannan, but displays little activity towards other polysaccharides located in the plant cell wall. Preferentially hydrolyzes the larger oligosaccharides

# Drug_Target_5_SwissProt_ID:
P49424

# Drug_Target_5_SwissProt_Name:
MANA_CELJU

# Drug_Target_5_Synonyms:
EC 3.2.1.78
Mannan endo-1,4-beta-mannosidase precursor
Mannanase A

# Drug_Target_5_Theoretical_pI:
5.46

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Membrane

# Drug_Target_6_Chromosome_Location:
1

# Drug_Target_6_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
Not Available

# Drug_Target_6_GenBank_ID_Gene:
AB025904

# Drug_Target_6_GenBank_ID_Protein:
6009640

# Drug_Target_6_GeneCard_ID:
CA14

# Drug_Target_6_Gene_Name:
CA14

# Drug_Target_6_Gene_Sequence:
>1014 bp
ATGTTGTTCTCCGCCCTCCTGCTGGAGGTGATTTGGATCCTGGCTGCAGATGGGGGTCAA
CACTGGACGTATGAGGGCCCACATGGTCAGGACCATTGGCCAGCCTCTTACCCTGAGTGT
GGAAACAATGCCCAGTCGCCCATCGATATTCAGACAGACAGTGTGACATTTGACCCTGAT
TTGCCTGCTCTGCAGCCCCACGGATATGACCAGCCTGGCACCGAGCCTTTGGACCTGCAC
AACAATGGCCACACAGTGCAACTCTCTCTGCCCTCTACCCTGTATCTGGGTGGACTTCCC
CGAAAATATGTAGCTGCCCAGCTCCACCTGCACTGGGGTCAGAAAGGATCCCCAGGGGGG
TCAGAACACCAGATCAACAGTGAAGCCACATTTGCAGAGCTCCACATTGTACATTATGAC
TCTGATTCCTATGACAGCTTGAGTGAGGCTGCTGAGAGGCCTCAGGGCCTGGCTGTCCTG
GGCATCCTAATTGAGGTGGGTGAGACTAAGAATATAGCTTATGAACACATTCTGAGTCAC
TTGCATGAAGTCAGGCATAAAGATCAGAAGACCTCAGTGCCTCCCTTCAACCTAAGAGAG
CTGCTCCCCAAACAGCTGGGGCAGTACTTCCGCTACAATGGCTCGCTCACAACTCCCCCT
TGCTACCAGAGTGTGCTCTGGACAGTTTTTTATAGAAGGTCCCAGATTTCAATGGAACAG
CTGGAAAAGCTTCAGGGGACATTGTTCTCCACAGAAGAGGAGCCCTCTAAGCTTCTGGTA
CAGAACTACCGAGCCCTTCAGCCTCTCAATCAGCGCATGGTCTTTGCTTCTTTCATCCAA
GCAGGATCCTCGTATACCACAGGTGAAATGCTGAGTCTAGGTGTAGGAATCTTGGTTGGC
TGTCTCTGCCTTCTCCTGGCTGTTTATTTCATTGCTAGAAAGATTCGGAAGAAGAGGCTG
GAAAACCGAAAGAGTGTGGTCTTCACCTCAGCACAAGCCACGACTGAGGCATAA

# Drug_Target_6_General_Function:
Inorganic ion transport and metabolism

# Drug_Target_6_General_References:
10512682	Fujikawa-Adachi K, Nishimori I, Taguchi T, Onishi S: Human carbonic anhydrase XIV (CA14): cDNA cloning, mRNA expression, and mapping to chromosome 1. Genomics. 1999 Oct 1;61(1):74-81.
12975309	Clark HF, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, Chen J, Chow B, Chui C, Crowley C, Currell B, Deuel B, Dowd P, Eaton D, Foster J, Grimaldi C, Gu Q, Hass PE, Heldens S, Huang A, Kim HS, Klimowski L, Jin Y, Johnson S, Lee J, Lewis L, Liao D, Mark M, Robbie E, Sanchez C, Schoenfeld J, Seshagiri S, Simmons L, Singh J, Smith V, Stinson J, Vagts A, Vandlen R, Watanabe C, Wieand D, Woods K, Xie MH, Yansura D, Yi S, Yu G, Yuan J, Zhang M, Zhang Z, Goddard A, Wood WI, Godowski P, Gray A: The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res. 2003 Oct;13(10):2265-70. Epub 2003 Sep 15.
14702039	Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
16710414	Gregory SG, Barlow KF, McLay KE, Kaul R, Swarbreck D, Dunham A, Scott CE, Howe KL, Woodfine K, Spencer CC, Jones MC, Gillson C, Searle S, Zhou Y, Kokocinski F, McDonald L, Evans R, Phillips K, Atkinson A, Cooper R, Jones C, Hall RE, Andrews TD, Lloyd C, Ainscough R, Almeida JP, Ambrose KD, Anderson F, Andrew RW, Ashwell RI, Aubin K, Babbage AK, Bagguley CL, Bailey J, Beasley H, Bethel G, Bird CP, Bray-Allen S, Brown JY, Brown AJ, Buckley D, Burton J, Bye J, Carder C, Chapman JC, Clark SY, Clarke G, Clee C, Cobley V, Collier RE, Corby N, Coville GJ, Davies J, Deadman R, Dunn M, Earthrowl M, Ellington AG, Errington H, Frankish A, Frankland J, French L, Garner P, Garnett J, Gay L, Ghori MR, Gibson R, Gilby LM, Gillett W, Glithero RJ, Grafham DV, Griffiths C, Griffiths-Jones S, Grocock R, Hammond S, Harrison ES, Hart E, Haugen E, Heath PD, Holmes S, Holt K, Howden PJ, Hunt AR, Hunt SE, Hunter G, Isherwood J, James R, Johnson C, Johnson D, Joy A, Kay M, Kershaw JK, Kibukawa M, Kimberley AM, King A, Knights AJ, Lad H, Laird G, Lawlor S, Leongamornlert DA, Lloyd DM, Loveland J, Lovell J, Lush MJ, Lyne R, Martin S, Mashreghi-Mohammadi M, Matthews L, Matthews NS, McLaren S, Milne S, Mistry S, Moore MJ, Nickerson T, O'Dell CN, Oliver K, Palmeiri A, Palmer SA, Parker A, Patel D, Pearce AV, Peck AI, Pelan S, Phelps K, Phillimore BJ, Plumb R, Rajan J, Raymond C, Rouse G, Saenphimmachak C, Sehra HK, Sheridan E, Shownkeen R, Sims S, Skuce CD, Smith M, Steward C, Subramanian S, Sycamore N, Tracey A, Tromans A, Van Helmond Z, Wall M, Wallis JM, White S, Whitehead SL, Wilkinson JE, Willey DL, Williams H, Wilming L, Wray PW, Wu Z, Coulson A, Vaudin M, Sulston JE, Durbin R, Hubbard T, Wooster R, Dunham I, Carter NP, McVean G, Ross MT, Harrow J, Olson MV, Beck S, Rogers J, Bentley DR, Banerjee R, Bryant SP, Burford DC, Burrill WD, Clegg SM, Dhami P, Dovey O, Faulkner LM, Gribble SM, Langford CF, Pandian RD, Porter KM, Prigmore E: The DNA sequence and biological annotation of human chromosome 1. Nature. 2006 May 18;441(7091):315-21.

# Drug_Target_6_HGNC_ID:
GNC:1372

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
6131

# Drug_Target_6_Locus:
1q21

# Drug_Target_6_Molecular_Weight:
37667.4

# Drug_Target_6_Name:
Carbonic anhydrase 14

# Drug_Target_6_Number_of_Residues:
337

# Drug_Target_6_PDB_ID:
Not Available

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF00194	Carb_anhydrase

# Drug_Target_6_Protein_Sequence:
>Carbonic anhydrase 14
MLFSALLLEVIWILAADGGQHWTYEGPHGQDHWPASYPECGNNAQSPIDIQTDSVTFDPD
LPALQPHGYDQPGTEPLDLHNNGHTVQLSLPSTLYLGGLPRKYVAAQLHLHWGQKGSPGG
SEHQINSEATFAELHIVHYDSDSYDSLSEAAERPQGLAVLGILIEVGETKNIAYEHILSH
LHEVRHKDQKTSVPPFNLRELLPKQLGQYFRYNGSLTTPPCYQSVLWTVFYRRSQISMEQ
LEKLQGTLFSTEEEPSKLLVQNYRALQPLNQRMVFASFIQAGSSYTTGEMLSLGVGILVG
CLCLLLAVYFIARKIRKKRLENRKSVVFTSAQATTEA

# Drug_Target_6_Reaction:
Not Available

# Drug_Target_6_Signals:
1-15

# Drug_Target_6_Specific_Function:
Reversible hydration of carbon dioxide

# Drug_Target_6_SwissProt_ID:
Q9ULX7

# Drug_Target_6_SwissProt_Name:
CAH14_HUMAN

# Drug_Target_6_Synonyms:
CA-XIV
Carbonate dehydratase XIV
Carbonic anhydrase XIV

# Drug_Target_6_Theoretical_pI:
6.34

# Drug_Target_6_Transmembrane_Regions:
291-311

# Drug_Target_7_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
RHO

# Drug_Target_7_GenBank_ID_Gene:
U49742

# Drug_Target_7_GenBank_ID_Protein:
1236137

# Drug_Target_7_GeneCard_ID:
RHO

# Drug_Target_7_Gene_Name:
RHO

# Drug_Target_7_Gene_Sequence:
>1047 bp
ATGAATGGCACAGAAGGCCCTAACTTCTACGTGCCCTTCTCCAATGCGACGGGTGTGGTA
CGCAGCCCCTTCGAGTACCCACAGTACTACCTGGCTGAGCCATGGCAGTTCTCCATGCTG
GCCGCCTACATGTTTCTGCTGATCGTGCTGGGCTTCCCCATCAACTTCCTCACGCTCTAC
GTCACCGTCCAGCACAAGAAGCTGCGCACGCCTCTCAACTACATCCTGCTCAACCTAGCC
GTGGCTGACCTCTTCATGGTCCTAGGTGGCTTCACCAGCACCCTCTACACCTCTCTGCAT
GGATACTTCGTCTTCGGGCCCACAGGATGCAATTTGGAGGGCTTCTTTGCCACCCTGGGC
GGTGAAATTGCCCTGTGGTCCTTGGTGGTCCTGGCCATCGAGCGGTACGTGGTGGTGTGT
AAGCCCATGAGCAACTTCCGCTTCGGGGAGAACCATGCCATCATGGGCGTTGCCTTCACC
TGGGTCATGGCGCTGGCCTGCGCCGCACCCCCACTCGCCGGCTGGTCCAGGTACATCCCC
GAGGGCCTGCAGTGCTCGTGTGGAATCGACTACTACACGCTCAAGCCGGAGGTCAACAAC
GAGTCTTTTGTCATCTACATGTTCGTGGTCCACTTCACCATCCCCATGATTATCATCTTT
TTCTGCTATGGGCAGCTCGTCTTCACCGTCAAGGAGGCCGCTGCCCAGCAGCAGGAGTCA
GCCACCACACAGAAGGCAGAGAAGGAGGTCACCCGCATGGTCATCATCATGGTCATCGCT
TTCCTGATCTGCTGGGTGCCCTACGCCAGCGTGGCATTCTACATCTTCACCCACCAGGGC
TCCAACTTCGGTCCCATCTTCATGACCATCCCAGCGTTCTTTGCCAAGAGCGCCGCCATC
TACAACCCTGTCATCTATATCATGATGAACAAGCAGTTCCGGAACTGCATGCTCACCACC
ATCTGCTGCGGCAAGAACCCACTGGGTGACGATGAGGCCTCTGCTACCGTGTCCAAGACG
GAGACGAGCCAGGTGGCCCCGGCCTAA

# Drug_Target_7_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_7_General_References:
1302614	Farrar GJ, Findlay JB, Kumar-Singh R, Kenna P, Humphries MM, Sharpe E, Humphries P: Autosomal dominant retinitis pigmentosa: a novel mutation in the rhodopsin gene in the original 3q linked family. Hum Mol Genet. 1992 Dec;1(9):769-71.
1391967	Fujiki K, Hotta Y, Hayakawa M, Sakuma H, Shiono T, Noro M, Sakuma T, Tamai M, Hikiji K, Kawaguchi R, et al.: Point mutations of rhodopsin gene found in Japanese families with autosomal dominant retinitis pigmentosa (ADRP). Jpn J Hum Genet. 1992 Jun;37(2):125-32.
1833777	Dryja TP, Hahn LB, Cowley GS, McGee TL, Berson EL: Mutation spectrum of the rhodopsin gene among patients with autosomal dominant retinitis pigmentosa. Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9370-4.
1840561	Gal A, Artlich A, Ludwig M, Niemeyer G, Olek K, Schwinger E, Schinzel A: Pro-347-Arg mutation of the rhodopsin gene in autosomal dominant retinitis pigmentosa. Genomics. 1991 Oct;11(2):468-70.
1862076	Sung CH, Davenport CM, Hennessey JC, Maumenee IH, Jacobson SG, Heckenlively JR, Nowakowski R, Fishman G, Gouras P, Nathans J: Rhodopsin mutations in autosomal dominant retinitis pigmentosa. Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6481-5.
1897520	Sheffield VC, Fishman GA, Beck JS, Kimura AE, Stone EM: Identification of novel rhodopsin mutations associated with retinitis pigmentosa by GC-clamped denaturing gradient gel electrophoresis. Am J Hum Genet. 1991 Oct;49(4):699-706.
1985460	Inglehearn CF, Bashir R, Lester DH, Jay M, Bird AC, Bhattacharya SS: A 3-bp deletion in the rhodopsin gene in a family with autosomal dominant retinitis pigmentosa. Am J Hum Genet. 1991 Jan;48(1):26-30.
2137202	Dryja TP, McGee TL, Reichel E, Hahn LB, Cowley GS, Yandell DW, Sandberg MA, Berson EL: A point mutation of the rhodopsin gene in one form of retinitis pigmentosa. Nature. 1990 Jan 25;343(6256):364-6.
2215617	Dryja TP, McGee TL, Hahn LB, Cowley GS, Olsson JE, Reichel E, Sandberg MA, Berson EL: Mutations within the rhodopsin gene in patients with autosomal dominant retinitis pigmentosa. N Engl J Med. 1990 Nov 8;323(19):1302-7.
2239971	Farrar GJ, Kenna P, Redmond R, McWilliam P, Bradley DG, Humphries MM, Sharp EM, Inglehearn CF, Bashir R, Jay M, et al.: Autosomal dominant retinitis pigmentosa: absence of the rhodopsin proline----histidine substitution (codon 23) in pedigrees from Europe. Am J Hum Genet. 1990 Dec;47(6):941-5.
6589631	Nathans J, Hogness DS: Isolation and nucleotide sequence of the gene encoding human rhodopsin. Proc Natl Acad Sci U S A. 1984 Aug;81(15):4851-5.
7633434	Macke JP, Hennessey JC, Nathans J: Rhodopsin mutation proline347-to-alanine in a family with autosomal dominant retinitis pigmentosa indicates an important role for proline at position 347. Hum Mol Genet. 1995 Apr;4(4):775-6.
7846071	Sieving PA, Richards JE, Naarendorp F, Bingham EL, Scott K, Alpern M: Dark-light: model for nightblindness from the human rhodopsin Gly-90-->Asp mutation. Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):880-4.
7981701	Fuchs S, Kranich H, Denton MJ, Zrenner E, Bhattacharya SS, Humphries P, Gal A: Three novel rhodopsin mutations (C110F, L131P, A164V) in patients with autosomal dominant retinitis pigmentosa. Hum Mol Genet. 1994 Jul;3(7):1203.
7987326	Antinolo G, Sanchez B, Borrego S, Rueda T, Chaparro P, Cabeza JC: Identification of a new mutation at codon 171 of rhodopsin gene causing autosomal dominant retinitis pigmentosa. Hum Mol Genet. 1994 Aug;3(8):1421.
7987331	Souied E, Gerber S, Rozet JM, Bonneau D, Dufier JL, Ghazi I, Philip N, Soubrane G, Coscas G, Munnich A, et al.: Five novel missense mutations of the rhodopsin gene in autosomal dominant retinitis pigmentosa. Hum Mol Genet. 1994 Aug;3(8):1433-4.
7987385	Kumaramanickavel G, Maw M, Denton MJ, John S, Srikumari CR, Orth U, Oehlmann R, Gal A: Missense rhodopsin mutation in a family with recessive RP. Nat Genet. 1994 Sep;8(1):10-1.
8045708	Rosas DJ, Roman AJ, Weissbrod P, Macke JP, Nathans J: Autosomal dominant retinitis pigmentosa in a large family: a clinical and molecular genetic study. Invest Ophthalmol Vis Sci. 1994 Jul;35(8):3134-44.
8076945	Reig C, Antich J, Gean E, Garcia-Sandoval B, Ramos C, Ayuso C, Carballo M: Identification of a novel rhodopsin mutation (Met-44-Thr) in a simplex case of retinitis pigmentosa. Hum Genet. 1994 Sep;94(3):283-6.
8081400	al-Maghtheh M, Inglehearn C, Lunt P, Jay M, Bird A, Bhattacharya S: Two new rhodopsin transversion mutations (L40R; M216K) in families with autosomal dominant retinitis pigmentosa. Hum Mutat. 1994;3(4):409-10.
8088850	Vaithinathan R, Berson EL, Dryja TP: Further screening of the rhodopsin gene in patients with autosomal dominant retinitis pigmentosa. Genomics. 1994 May 15;21(2):461-3.
8317502	Macke JP, Davenport CM, Jacobson SG, Hennessey JC, Gonzalez-Fernandez F, Conway BP, Heckenlively J, Palmer R, Maumenee IH, Sieving P, et al.: Identification of novel rhodopsin mutations responsible for retinitis pigmentosa: implications for the structure and function of rhodopsin. Am J Hum Genet. 1993 Jul;53(1):80-9.
8353500	Kranich H, Bartkowski S, Denton MJ, Krey S, Dickinson P, Duvigneau C, Gal A: Autosomal dominant 'sector' retinitis pigmentosa due to a point mutation predicting an Asn-15-Ser substitution of rhodopsin. Hum Mol Genet. 1993 Jun;2(6):813-4.
8358437	Dryja TP, Berson EL, Rao VR, Oprian DD: Heterozygous missense mutation in the rhodopsin gene as a cause of congenital stationary night blindness. Nat Genet. 1993 Jul;4(3):280-3.
8401533	al-Maghtheh M, Gregory C, Inglehearn C, Hardcastle A, Bhattacharya S: Rhodopsin mutations in autosomal dominant retinitis pigmentosa. Hum Mutat. 1993;2(4):249-55.
8554077	Souied E, Soubrane G, Benlian P, Coscas GJ, Gerber S, Munnich A, Kaplan J: Retinitis punctata albescens associated with the Arg135Trp mutation in the rhodopsin gene. Am J Ophthalmol. 1996 Jan;121(1):19-25.
9452035	Goliath R, Bardien S, September A, Martin R, Ramesar R, Greenberg J: Rhodopsin mutation G109R in a family with autosomal dominant retinitis pigmentosa. Hum Mutat. 1998;Suppl 1:S40-1.
9888392	al-Jandal N, Farrar GJ, Kiang AS, Humphries MM, Bannon N, Findlay JB, Humphries P, Kenna PF: A novel mutation within the rhodopsin gene (Thr-94-Ile) causing autosomal dominant congenital stationary night blindness. Hum Mutat. 1999;13(1):75-81.

# Drug_Target_7_HGNC_ID:
HGNC:10012

# Drug_Target_7_HPRD_ID:
01584

# Drug_Target_7_ID:
2207

# Drug_Target_7_Locus:
3q21-q24

# Drug_Target_7_Molecular_Weight:
38893

# Drug_Target_7_Name:
Rhodopsin

# Drug_Target_7_Number_of_Residues:
348

# Drug_Target_7_PDB_ID:
1LN6

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_7_Protein_Sequence:
>Rhodopsin
MNGTEGPNFYVPFSNATGVVRSPFEYPQYYLAEPWQFSMLAAYMFLLIVLGFPINFLTLY
VTVQHKKLRTPLNYILLNLAVADLFMVLGGFTSTLYTSLHGYFVFGPTGCNLEGFFATLG
GEIALWSLVVLAIERYVVVCKPMSNFRFGENHAIMGVAFTWVMALACAAPPLAGWSRYIP
EGLQCSCGIDYYTLKPEVNNESFVIYMFVVHFTIPMIIIFFCYGQLVFTVKEAAAQQQES
ATTQKAEKEVTRMVIIMVIAFLICWVPYASVAFYIFTHQGSNFGPIFMTIPAFFAKSAAI
YNPVIYIMMNKQFRNCMLTTICCGKNPLGDDEASATVSKTETSQVAPA

# Drug_Target_7_Reaction:
Not Available

# Drug_Target_7_Signals:
None

# Drug_Target_7_Specific_Function:
Visual pigments are the light-absorbing molecules that mediate vision. They consist of an apoprotein, opsin, covalently linked to cis-retinal

# Drug_Target_7_SwissProt_ID:
P08100

# Drug_Target_7_SwissProt_Name:
OPSD_HUMAN

# Drug_Target_7_Synonyms:
Opsin-2

# Drug_Target_7_Theoretical_pI:
6.64

# Drug_Target_7_Transmembrane_Regions:
37-61
74-98
114-133
153-176
203-230
253-276
285-309

# Drug_Target_8_Cellular_Location:
Microsome
microsomal membrane
peripheral membrane protein

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
PTGS1

# Drug_Target_8_GenBank_ID_Gene:
M31822

# Drug_Target_8_GenBank_ID_Protein:
387018

# Drug_Target_8_GeneCard_ID:
PTGS1

# Drug_Target_8_Gene_Name:
PTGS1

# Drug_Target_8_Gene_Sequence:
>1800 bp
ATGAGCCGGAGTCTCTTGCTCCGGTTCTTGCTGTTGCTGCTCCTGCTCCCGCCGCTCCCC
GTCCTGCTCGCGGACCCAGGGGCGCCCACGCCAGTGAATCCCTGTTGTTACTATCCATGC
CAGCACCAGGGCATCTGTGTCCGCTTCGGCCTTGACCGCTACCAGTGTGACTGCACCCGC
ACGGGCTATTCCGGCCCCAACTGCACCATCCCTGGCCTGTGGACCTGGCTCCGGAATTCA
CTGCGGCCCAGCCCCTCTTTCACCCACTTCCTGCTCACTCACGGGCGCTGGTTCTGGGAG
TTTGTCAATGCCACCTTCATCCGAGAGATGCTCATGCTCCTGGTACTCACAGTGCGCTCC
AACCTTATCCCCAGTCCCCCCACCTACAACTCTGCACATGACTACATCAGCTGGGAGTCT
TTCTCCAACGTGAGCTATTACACTCGTATTCTGCCCTCTGTGCCTAAAGATTGCCCCACA
CCCATGGGAACCAAAGGGAAGAAGCAGTTGCCAGATGCCCAGCTCCTGGCCCGCCGCTTC
CTGCTCAGGAGGAAGTTCATACCTGACCCCCAAGGCACCAACCTCATGTTTGCCTTCTTT
GCACAACACTTCACCCACCAGTTCTTCAAAACTTCTGGCAAGATGGGTCCTGGCTTCACC
AAGGCCTTGGGCCATGGGGTAGACCTCGGCCACATTTATGGAGACAATCTGGAGCGTCAG
TATCAACTGCGGCTCTTTAAGGATGGGAAACTCAAGTACCAGGTGCTGGATGGAGAAATG
TACCCGCCCTCGGTAGAAGAGGCGCCTGTGTTGATGCACTACCCCCGAGGCATCCCGCCC
CAGAGCCAGATGGCTGTGGGCCAGGAGGTGTTTGGGCTGCTTCCTGGGCTCATGCTGTAT
GCCACGCTCTGGCTACGTGAGCACAACCGTGTGTGTGACCTGCTGAAGGCTGAGCACCCC
ACCTGGGGCGATGAGCAGCTTTTCCAGACGACCCGCCTCATCCTCATAGGGGAGACCATC
AAGATTGTCATCGAGGAGTACGTGCAGCAGCTGAGTGGCTATTTCCTGCAGCTGAAATTT
GACCCAGAGCTGCTGTTCGGTGTCCAGTTCCAATACCGCAACCGCATTGCCACGGAGTTC
AACCATCTCTACCACTGGCACCCCCTCATGCCTGACTCCTTCAAGGTGGGCTCCCAGGAG
TACAGCTACGAGCAGTTCTTGTTCAACACCTCCATGTTGGTGGACTATGGGGTTGAGGCC
CTGGTGGATGCCTTCTCTCGCCAGATTGCTGGCCGGATCGGTGGGGGCAGGAACATGGAC
CACCACATCCTGCATGTGGCTGTGGATGTCATCAGGGAGTCTCGGGAGATGCGGCTGCAG
CCCTTCAATGAGTACCGCAAGAGGTTTGGCATGAAACCCTACACCTCCTTCCAGGAGCTC
GTAGGAGAGAAGGAGATGGCAGCAGAGTTGGAGGAATTGTATGGAGACATTGATGCGTTG
GAGTTCTACCCTGGACTGCTTCTTGAAAAGTGCCATCCAAACTCTATCTTTGGGGAGAGT
ATGATAGAGATTGGGGCTCCCTTTTCCCTCAAGGGTCTCCTAGGGAATCCCATCTGTTCT
CCGGAGTACTGGAAGCCGAGCACATTTGGCGGCGAGGTGGGCTTTAACATTGTCAAGACG
GCCACACTGAAGAAGCTGGTCTGCCTCAACACCAAGACCTGTCCCTACGTTTCCTTCCGT
GTGCCGGATGCCAGTCAGGATGATGGGCCTGCTGTGGAGCGACCATCCACAGAGCTCTGA

# Drug_Target_8_General_Function:
Involved in peroxidase activity

# Drug_Target_8_General_References:
1587858	Diaz A, Reginato AM, Jimenez SA: Alternative splicing of human prostaglandin G/H synthase mRNA and evidence of differential regulation of the resulting transcripts by transforming growth factor beta 1, interleukin 1 beta, and tumor necrosis factor alpha. J Biol Chem. 1992 May 25;267(15):10816-22.
1734857	Takahashi Y, Ueda N, Yoshimoto T, Yamamoto S, Yokoyama C, Miyata A, Tanabe T, Fuse I, Hattori A, Shibata A: Immunoaffinity purification and cDNA cloning of human platelet prostaglandin endoperoxide synthase (cyclooxygenase). Biochem Biophys Res Commun. 1992 Jan 31;182(2):433-8.
1907252	Funk CD, Funk LB, Kennedy ME, Pong AS, Fitzgerald GA: Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J. 1991 Jun;5(9):2304-12.
2512924	Yokoyama C, Tanabe T: Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. Biochem Biophys Res Commun. 1989 Dec 15;165(2):888-94.

# Drug_Target_8_HGNC_ID:
HGNC:9604

# Drug_Target_8_HPRD_ID:
07518

# Drug_Target_8_ID:
20

# Drug_Target_8_Locus:
9q32-q33.3

# Drug_Target_8_Molecular_Weight:
68657

# Drug_Target_8_Name:
Prostaglandin G/H synthase 1

# Drug_Target_8_Number_of_Residues:
599

# Drug_Target_8_PDB_ID:
Not Available

# Drug_Target_8_Pathway:
Abciximab Pathway	SMP00265
Acetylsalicylic Acid Pathway	SMP00083
Bromfenac Pathway	SMP00102
Celecoxib Pathway	SMP00096
Cilostazol Pathway	SMP00263
Clopidogrel Pathway	SMP00260
Diclofenac Pathway	SMP00093
Diflunisal Pathway	SMP00289
Dipyridamole (Antiplatelet) Pathway	SMP00264
Eptifibatide Pathway	SMP00266
Etodolac Pathway	SMP00084
Ibuprofen Pathway	SMP00086
Indomethacin Pathway	SMP00104
Ketoprofen Pathway	SMP00085
Ketorolac Pathway	SMP00098
Mefanamic Acid Pathway	SMP00109
Meloxicam Pathway	SMP00106
Nabumetone Pathway	SMP00114
Naproxen Pathway	SMP00120
Oxaprozin Pathway	SMP00113
Piroxicam Pathway	SMP00077
Rofecoxib Pathway	SMP00087
Sulindac Pathway	SMP00094
Suprofen Pathway	SMP00101
Ticlopidine Pathway	SMP00261
Tirofiban Pathway	SMP00267
Valdecoxib Pathway	SMP00116

# Drug_Target_8_Pfam_Domain_Function:
PF00008	EGF
PF03098	An_peroxidase

# Drug_Target_8_Protein_Sequence:
>Prostaglandin G/H synthase 1 precursor
MSRSLLLRFLLFLLLLPPLPVLLADPGAPTPVNPCCYYPCQHQGICVRFGLDRYQCDCTR
TGYSGPNCTIPGLWTWLRNSLRPSPSFTHFLLTHGRWFWEFVNATFIREMLMRLVLTVRS
NLIPSPPTYNSAHDYISWESFSNVSYYTRILPSVPKDCPTPMGTKGKKQLPDAQLLARRF
LLRRKFIPDPQGTNLMFAFFAQHFTHQFFKTSGKMGPGFTKALGHGVDLGHIYGDNLERQ
YQLRLFKDGKLKYQVLDGEMYPPSVEEAPVLMHYPRGIPPQSQMAVGQEVFGLLPGLMLY
ATLWLREHNRVCDLLKAEHPTWGDEQLFQTTRLILIGETIKIVIEEYVQQLSGYFLQLKF
DPELLFGVQFQYRNRIAMEFNHLYHWHPLMPDSFKVGSQEYSYEQFLFNTSMLVDYGVEA
LVDAFSRQIAGRIGGGRNMDHHILHVAVDVIRESREMRLQPFNEYRKRFGMKPYTSFQEL
VGEKEMAAELEELYGDIDALEFYPGLLLEKCHPNSIFGESMIEIGAPFSLKGLLGNPICS
PEYWKPSTFGGEVGFNIVKTATLKKLVCLNTKTCPYVSFRVPDASQDDGPAVERPSTEL

# Drug_Target_8_Reaction:
arachidonate + AH2 + 2 O2 = prostaglandin H2 + A + H2O

# Drug_Target_8_Signals:
1-23

# Drug_Target_8_Specific_Function:
May play an important role in regulating or promoting cell proliferation in some normal and neoplastically transformed cells

# Drug_Target_8_SwissProt_ID:
P23219

# Drug_Target_8_SwissProt_Name:
PGH1_HUMAN

# Drug_Target_8_Synonyms:
COX-1
Cyclooxygenase- 1
EC 1.14.99.1
PGH synthase 1
PGHS-1
PHS 1
Prostaglandin G/H synthase 1 precursor
Prostaglandin H2 synthase 1
Prostaglandin-endoperoxide synthase 1

# Drug_Target_8_Theoretical_pI:
7.39

# Drug_Target_8_Transmembrane_Regions:
None

# Drug_Target_9_Cellular_Location:
Cytoplasmic

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
BCHE

# Drug_Target_9_GenBank_ID_Gene:
M32391

# Drug_Target_9_GenBank_ID_Protein:
1311630

# Drug_Target_9_GeneCard_ID:
BCHE

# Drug_Target_9_Gene_Name:
BCHE

# Drug_Target_9_Gene_Sequence:
>1809 bp
ATGCATAGCAAAGTCACAATCATATGCATCAGATTTCTCTTTTGGTTTCTTTTGCTCTGC
ATGCTTATTGGGAAGTCACATACTGAAGATGACATCATAATTGCAACAAAGAATGGAAAA
GTCAGAGGGATGAACTTGACAGTTTTTGGTGGCACGGTAACAGCCTTTCTTGGAATTCCC
TATGCACAGCCACCTCTTGGTAGACTTCGATTCAAAAAGCCACAGTCTCTGACCAAGTGG
TCTGATATTTGGAATGCCACAAAATATGCAAATTCTTGCTGTCAGAACATAGATCAAAGT
TTTCCAGGCTTCCATGGATCAGAGATGTGGAACCCAAACACTGACCTCAGTGAAGACTGT
TTATATCTAAATGTATGGATTCCAGCACCTAAACCAAAAAATGCCACTGTATTGATATGG
ATTTATGGTGGTGGTTTTCAAACTGGAACATCATCTTTACATGTTTATGATGGCAAGTTT
CTGGCTCGGGTTGAAAGAGTTATTGTAGTGTCAATGAACTATAGGGTGGGTGCCCTAGGA
TTCTTAGCTTTGCCAGGAAATCCTGAGGCTCCAGGGAACATGGGTTTATTTGATCAACAG
TTGGCTCTTCAGTGGGTTCAAAAAAATATAGCAGCCTTTGGTGGAAATCCTAAAAGTGTA
ACTCTCTTTGGAGAAAGTGCAGGAGCAGCTTCAGTTAGCCTGCATTTGCTTTCTCCTGGA
AGCCATTCATTGTTCACCAGAGCCATTCTGCAAAGTGGATCCTTTAATGCTCCTTGGGCG
GTAACATCTCTTTATGAAGCTAGGAACAGAACGTTGAACTTAGCTAAATTGACTGGTTGC
TCTAGAGAGAATGAGACTGAAATAATCAAGTGTCTTAGAAATAAAGATCCCCAAGAAATT
CTTCTGAATGAAGCATTTGTTGTCCCCTATGGGACTCCTTTGTCAGTAAACTTTGGTCCG
ACCGTGGATGGTGATTTTCTCACTGACATGCCAGACATATTACTTGAACTTGGACAATTT
AAAAAAACCCAGATTTTGGTGGGTGTTAATAAAGATGAAGGGACAGCTTTTTTAGTCTAT
GGTGCTCCTGGCTTCAGCAAAGATAACAATAGTATCATAACTAGAAAAGAATTTCAGGAA
GGTTTAAAAATATTTTTTCCAGGAGTGAGTGAGTTTGGAAAGGAATCCATCCTTTTTCAT
TACACAGACTGGGTAGATGATCAGAGACCTGAAAACTACCGTGAGGCCTTGGGTGATGTT
GTTGGGGATTATAATTTCATATGCCCTGCCTTGGAGTTCACCAAGAAGTTCTCAGAATGG
GGAAATAATGCCTTTTTCTACTATTTTGAACACCGATCCTCCAAACTTCCGTGGCCAGAA
TGGATGGGAGTGATGCATGGCTATGAAATTGAATTTGTCTTTGGTTTACCTCTGGAAAGA
AGAGATAATTACACAAAAGCCGAGGAAATTTTGAGTAGATCCATAGTGAAACGTTGGGCA
AATTTTGCAAAATATGGGAATCCAAATGAGACTCAGAACAATAGCACAAGCTGGCCTGTC
TTCAAAAGCACTGAACAAAAATATCTAACCTTGAATACAGAGTCAACAAGAATAATGACG
AAACTACGTGCTCAACAATGTCGATTCTGGACATCATTTTTTCCAAAAGTCTTGGAAATG
ACAGGAAATATTGATGAAGCAGAATGGGAGTGGAAAGCAGGATTCCATCGCTGGAACAAT
TACATGATGGACTGGAAAAATCAATTTAACGATTACACTAGCAAGAAAGAAAGTTGTGTG
GGTCTCTAA

# Drug_Target_9_General_Function:
Lipid transport and metabolism

# Drug_Target_9_General_References:
2322535	Arpagaus M, Kott M, Vatsis KP, Bartels CF, La Du BN, Lockridge O: Structure of the gene for human butyrylcholinesterase. Evidence for a single copy. Biochemistry. 1990 Jan 9;29(1):124-31.
2915989	McGuire MC, Nogueira CP, Bartels CF, Lightstone H, Hajra A, Van der Spek AF, Lockridge O, La Du BN: Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase. Proc Natl Acad Sci U S A. 1989 Feb;86(3):953-7.
3035536	Prody CA, Zevin-Sonkin D, Gnatt A, Goldberg O, Soreq H: Isolation and characterization of full-length cDNA clones coding for cholinesterase from fetal human tissues. Proc Natl Acad Sci U S A. 1987 Jun;84(11):3555-9.
3067729	Lockridge O: Structure of human serum cholinesterase. Bioessays. 1988 Oct;9(4):125-8.
3115973	Lockridge O, Adkins S, La Du BN: Location of disulfide bonds within the sequence of human serum cholinesterase. J Biol Chem. 1987 Sep 25;262(27):12945-52.
3477799	McTiernan C, Adkins S, Chatonnet A, Vaughan TA, Bartels CF, Kott M, Rosenberry TL, La Du BN, Lockridge O: Brain cDNA clone for human cholinesterase. Proc Natl Acad Sci U S A. 1987 Oct;84(19):6682-6.
3542989	Lockridge O, Bartels CF, Vaughan TA, Wong CK, Norton SE, Johnson LL: Complete amino acid sequence of human serum cholinesterase. J Biol Chem. 1987 Jan 15;262(2):549-57.

# Drug_Target_9_HGNC_ID:
HGNC:983

# Drug_Target_9_HPRD_ID:
01519

# Drug_Target_9_ID:
3923

# Drug_Target_9_Locus:
3q26.1-q26.2

# Drug_Target_9_Molecular_Weight:
68419

# Drug_Target_9_Name:
Cholinesterase

# Drug_Target_9_Number_of_Residues:
602

# Drug_Target_9_PDB_ID:
1P0Q

# Drug_Target_9_Pathway:
Heroin Pathway	SMP00407
Irinotecan Pathway	SMP00433

# Drug_Target_9_Pfam_Domain_Function:
PF00135	COesterase
PF08674	AChE_tetra

# Drug_Target_9_Protein_Sequence:
>Cholinesterase
MHSKVTIICIRFLFWFLLLCMLIGKSHTEDDIIIATKNGKVRGMNLTVFGGTVTAFLGIP
YAQPPLGRLRFKKPQSLTKWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDC
LYLNVWIPAPKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGALG
FLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESAGAASVSLHLLSPG
SHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLTGCSRENETEIIKCLRNKDPQEI
LLNEAFVVPYGTPLSVNFGPTVDGDFLTDMPDILLELGQFKKTQILVGVNKDEGTAFLVY
GAPGFSKDNNSIITRKEFQEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDV
VGDYNFICPALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPLER
RDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKYLTLNTESTRIMT
KLRAQQCRFWTSFFPKVLEMTGNIDEAEWEWKAGFHRWNNYMMDWKNQFNDYTSKKESCV
GL

# Drug_Target_9_Reaction:
an acylcholine + H2O = choline + a carboxylate

# Drug_Target_9_Signals:
1-28

# Drug_Target_9_Specific_Function:
An acylcholine + H(2)O = choline + a carboxylate

# Drug_Target_9_SwissProt_ID:
P06276

# Drug_Target_9_SwissProt_Name:
CHLE_HUMAN

# Drug_Target_9_Synonyms:
Acylcholine acylhydrolase
Butyrylcholine esterase
Choline esterase II
Cholinesterase precursor
EC 3.1.1.8
Pseudocholinesterase

# Drug_Target_9_Theoretical_pI:
7.47

# Drug_Target_9_Transmembrane_Regions:
None

#END_DRUGCARD DB02687
